Computational study targeting anti-fungal Tavaborole analogs and anti-cancer BRACO19 by Machireddy, Babitha
Rowan University 
Rowan Digital Works 
Theses and Dissertations 
11-2-2017 
Computational study targeting anti-fungal Tavaborole analogs 
and anti-cancer BRACO19 
Babitha Machireddy 
Rowan University 
Follow this and additional works at: https://rdw.rowan.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Let us know how access to this document benefits you - 
share your thoughts on our feedback form. 
Recommended Citation 
Machireddy, Babitha, "Computational study targeting anti-fungal Tavaborole analogs and anti-cancer 
BRACO19" (2017). Theses and Dissertations. 2479. 
https://rdw.rowan.edu/etd/2479 
This Thesis is brought to you for free and open access by Rowan Digital Works. It has been accepted for inclusion 
in Theses and Dissertations by an authorized administrator of Rowan Digital Works. For more information, please 
contact LibraryTheses@rowan.edu. 
 
COMPUTATIONAL STUDY TARGETING ANTI-FUNGAL TAVABOROLE 













Submitted to the 
Department of Chemistry and Biochemistry 
College of Science and Mathematics 
In partial fulfillment of the requirement 
For the degree of 
Master of Science in Pharmaceutical Sciences 
at 
Rowan University 
October 18, 2017 
 
 





I would like to dedicate this manuscript to Professor Kandalam Ramanujachary, 
Ph.D. To whom, I am forever indebted. He is my role model and a source of inspiration. 




I would like to take this opportunity to thank Dr. Chun Wu for guiding and 
motivating me through this course. His impossible standards for humbled me and 
encouraged me to become a better student. I would like to thank Dr. Subash C 
Jonnalagadda for giving me this incredible opportunity to work on this project. The level 
of perfection he anticipates from his students nurtured the perfectionist in me. I would like 
to thank Dr. Kandalam Ramanujachary for the constant encouragement, support and 
guidance. And I would like thank Gayathri Jampana for the ocean of kindness she showed 
to a total stranger. Finally, I would like to thank Rowan University, Department of 
Chemistry and Biochemistry for giving me this incredible opportunity.  
 This work was supported by Rowan Startup and SEED grant and the National 






COMPUTATIONAL STUDY TARGETING ANTI-FUNGAL TAVABOROLE 
ANALOGS AND ANTI-CANCER BRACO19 
2017-2018 
Chun Wu, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
 
This thesis comprises of three computer aided drug design studies utilizing 
molecular docking and molecular dynamic simulations: (i) a lead optimization study 
virtually screening an initial library of ~120000 lead compounds targeting fungal leucyl 
tRNA synthetase, (ii) an exploratory study to understand the binding pathway of 
BRACO19 to a parallel telomeric DNA G-quadruplex by MD simulations and compare 
with experimentally solved X-ray crystal structure (iii) a comparative study to understand 
the lack of selectivity of BRACO19 to various topologies of human telomeric DNA G-
quadruplex over DNA duplex. 
The first chapter provides the background information required to understand the 
molecular docking studies and molecular dynamics simulation (MD) studies conducted and 
discussed in this thesis. This introductory chapter is organized as follows: the first section 
is an introduction to molecular recognition in protein-ligand interactions, the second 
section introduces computer-aided drug design, the third section introduces homology 
modelling, the fourth section discusses molecular docking and virtual screening, the fifth 
section introduces methods for binding affinity prediction and the sixth section explains 
MD simulations. 
The second chapter of this thesis proposes a library of compounds with enhanced 
activity compared to the parent molecule it had been modified from. Tavaborole, the 
 
vi 
recently approved topological anti-fungal drug, inhibits leucyl tRNA synthetase by 
irreversible covalent bonding and hinders protein synthesis. The benzo-boroxole 
pharmacophore of tavaborole is responsible for its unique activity. This study theoretically 
proposes molecules with improved anti-fungal affinity. 
The third chapter of this thesis explores the binding pathway of anti-cancer drug, 
BRACO19 and human telomeric DNA G-quadruplex. G-quadruplex specific ligands that 
stabilizes the G-quadruplex, have great potential to be developed as anticancer agents. A 
free human telomeric DNA G-quadruplex and an unbound BRACO19 are simulated and 
the resulting structure is then compared with an experimentally solved X-ray structure of 
human telomeric G-quadruplex with a bound BRACO19 intercalated within the G-
quadruplex. Three binding modes have been identified: top end stacking, bottom 
intercalation and groove binding. Bottom intercalation mode (51% of the population) is 
identical to the binding pose in the X-ray solved crystal structure. 
The fourth chapter of this thesis compares different topological folds of human 
telomeric DNA G-quadruplexes (parallel, antiparallel and hybrid) that have been 
experimentally solved using molecular dynamic simulation to understand the 62-fold 
preferential selectivity of BRACO19 towards human telomeric DNA G-quadruplex over 
DNA duplex. Groove binding mode was found to be the most stable binding mode for the 
duplex and top stacking mode for the G-quadruplexes. The non-existential binding 
selectivity of BRACO19 can be accounted to the similar groove binding to both the duplex 
and the G-quadruplex. For that reason, a modification should be induced such that this 
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Chapter 1  
Introduction to Computer-Aided Drug Design 
1.1 Introduction 
Based on principles of molecular recognition, computer-aided drug design (CADD) 
utilizes the increasing computational power to develop and employ various theoretical 
models for drug discovery and design. Over the years, computer-aided drug design 
(CADD) demonstrated to be effective and instrumental in influencing drug discovery and 
molecular recognition. Even though the fast computational tools are not absolutely accurate 
due to the resources, time and manpower required to perform experimental methods to gain 
the same insights renders CADD very valuable for drug discovery and design.(Tang, 2010)  
The subject of designing drugs with high affinity for specific biological receptors 
is of continuing intellectual and practical interest. Molecular simulations and molecular 
modelling studies provide insights about the interactions contributing to the association of 
biological molecules. Before designing a model that can simulate association or 
dissociation of biological molecules, a systematic and exhaustive understanding of 
molecular recognition is essential. (Lamb & Jorgensen, 1997) The molecular establishment 
of many ubiquitous and crucial biological functions is formed by protein-ligand 
interactions. A rational guide to therapeutic drug design is attained by understanding the 
qualitative and quantitative components of the physical forces governing the protein-ligand 
interactions. Therefore, it is of immense scientific and practical importance to understand 
the role of molecular recognition in protein-ligand interactions. 
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1.2 Molecular Recognition 
Molecular recognition is the non-covalent interactions between two or more 
molecules through van der Waals forces, hydrogen bonding, metal coordination and π-π, 
hydrophobic, or electrostatic interactions. Molecular recognition mediates interactions 
between receptors and ligands, proteins and proteins, nucleic acids and proteins, antigens 
and antibodies, enzymes and substrates etc. (Cleaves, 2011) Molecular recognition is 
defined by two characteristics: (i) affinity; governed by the strength of non-covalent 
interactions and (ii) specificity; relative strength of those non-covalent interactions with 
respect to another ligand/receptor. (Demchenko, 2001)  Understanding the mechanisms of 
protein function is to understand the protein–ligand interactions. Therefore, it is crucial to 
understand the characterization and quantification of the energetics that govern the 
formation of a protein–ligand complex (Perozzo, Folkers, & Scapozza, 2004).  
1.2.1 Affinity and specificity. The change in binding free energy of the complex 
compared with other potential targets determine the affinity and specificity of protein-
ligand interactions. (Tang, 2010) One of the most significant thermodynamic quantities 
used to characterize the driving force is Gibbs free (binding) energy (G°). It indicates the 
capacity of a thermodynamic system to do maximum or reversible work at isothermal and 
isobaric conditions. A protein–ligand–solvent system is considered as a simple solute-
solvent thermodynamic system, where the protein and ligand molecules are solutes and 
liquid water and buffer ions make a solvent system. Accordingly, thermodynamic laws 
dictate the interactions between them, resulting heat transfer and how these energy changes 




Change in binding (Gibbs) free energy (∆G°) depends on two independent 
thermodynamics entities: change in enthalpy (∆H°) and change in entropy (∆S°) written 
as, 
∆G° = ∆H° − T∆S° (Pirzadeh, Beaudoin, & Kusalik, 2012)     (1.1) 
It should be noted that the free energy (∆G°) is defined merely by the initial and 
final thermodynamic states, regardless of the pathway connecting these two states. (Du et 
al., 2016)  
1.2.1.1 Enthalpy. Enthalpy (∆H°) is the total energy of the system, i.e., the sum of 
the internal energies of the solute and solvent and the energy required to solvate the system. 
(Li, Xie, Liu, & Liu, 2014) In general, the binding enthalpy of a thermodynamic system is 
the change in energy as a consequence of noncovalent interactions formed (van der Waals 
forces, hydrogen bonding, metal coordination and π-π, hydrophobic, or electrostatic 
interactions) at the binding site. (Perozzo et al., 2004) 
1.2.1.2 Entropy. Entropy (∆S°) is the disorder or randomness of atoms and 
molecules in the system. The binding entropy (∆S°) (the total entropy change associated 
with binding) can be broken down into solvent entropy change (∆SS°), conformational 
entropy change (∆SC°) and translational and rotational degrees of freedom lost due to the 
formation of protein-ligand complex (∆ST°): 
∆S° = ∆SS° + ∆SC° + ∆ST° (Du et al., 2016)       (1.2) 
In protein-ligand complex formation, the binding entropy (∆S°) is mostly derived 
from solvation, de-solvation and the degrees of freedom of both ligand and protein during 
complex formation. When the ligand is transferred from the hydrophilic solvent to the 
predominantly hydrophobic binding site, entropy change of the ligand (∆SL) can be split 
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into conformational entropy (∆SC°) (accessible rotamers), configurational entropy (∆ST°) 
(translational and rotational), and vibrational entropy (∆SV°) as follows, 
∆SL°= ∆SC°+ ∆ST°+ ∆SV°         (1.3) 
Entropy change of the protein (∆SP) can also be split into the same components as 
the ligand. However, under the assumption that the entropy change in the protein is 
negligible, essential simplification of the model does not consider entropy change in the 
protein (∆SP) when bound to different ligands. 
1.2.2 Challenges in entropy estimation. As mentioned in 1.2.1.2 solvation and 
de-solvation of both protein and ligand contribute to the entropic changes. Additionally, 
multiple binding states, entropy-entropy compensation, and configurational entropy also 
contribute to the entropic changes. These entropic changes are both challenging and 
energetically critical to accurately model the heuristic methods. Various theoretical 
methods were employed to estimate the solvation energies involved in protein-ligand 
interactions. Theoretical studies including MD simulations and intrinsic solvent 
representation (MM-GBSA, MM-PBSA, etc.) have been developed and applied.  
While docking the ligands into the binding site, the flexibility of the same is 
ignored. Accounting to this oversimplification to reduce the computational expense, 
docking ignores enthalpy-entropy compensation. This compensation, an effect of the 
receptor’s assumed rigidity, contributes to inaccurate entropy estimation. 
1.3 Homology Modeling 
3D structure of a protein can be obtained using X-ray crystallography or NMR 
spectroscopy studies are available in the Protein Data Bank (PDB) (Westbrook, Feng, 
Chen, Yang, & Berman, 2003), http://www.rcsb.org/pdb. However, when the 3D structure 
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of a protein is unknown, a theoretical protein model can be generated based on a 
homologous protein with known 3D structure. A technique known as homology modeling 
predicts the 3D structure of the protein utilizing its amino-acid sequence and the topology 
of the homologous protein (template). (Withana-Gamage, Hegedus, Qiu, & Wanasundara, 
2011) This technique is based on the structural similarity of evolutionarily related proteins. 
(Chandonia & Brenner, 2005; Vitkup, Melamud, Moult, & Sander, 2001) 
Generating a homology model of an amino-acid sequence is a multi-step process: 
(i) template identification, (ii) sequence alignments and (iii) model building (Joo, Lee, & 
Lee, 2012) (Vyas, Ukawala, Ghate, & Chintha, 2012). 
1.4 Protein–Ligand Binding Models 
Binding mechanisms of proteins and ligands have been explained by three known 
models; the lock-and-key (E.  Fischer, 1894), induced fit (Koshland, 1958) and 
conformational selection (Csermely, Palotai, & Nussinov, 2010; Du et al., 2016; Ma, 






Figure 1. Three protein models; (A) lock-and-key model, (B) induced fit model and (C) 




1.4.1 The lock-and-key model. The lock-and-key model (Figure1A) employs a 
rigid ligand being fit into a rigid binding site of a rigid protein, where the ligand fits into 
the binding pocket like a key in a lock. However, this mechanism conflicted the 
experimental evidence demonstrated by the protein-ligand complexes whose initial protein 
and ligand structures did not resemble the final structure. 
1.4.2 The induced fit model. Contrary to the lock-and-key model, the induced fit 
model (Figure 1B) employs a flexible binding site in the protein and a conformational 
change is induced at the binding pocket by the approaching ligand. This model illustrates 
the binding mechanism of the protein-ligand complex demonstrating minor conformational 
changes after the ligand binding at the binding site.  
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1.4.3 The conformational selection model. One main characteristic assumption in 
both induced fit and lock-and-key models is that the protein adopts a singular, stable 
conformation throughout the binding process. But, most proteins are inherently dynamic. 
And the conformational selection model considers this inherent flexibility.  
The conformational selection model (Figure 1C) defines protein with its implicit 
flexibility based on the free energy landscape (FEL) theory of protein structure and 
dynamics. (Bryngelson, Onuchic, Socci, & Wolynes, 1995; Frauenfelder, Sligar, & 
Wolynes, 1991; Henzler-Wildman & Kern, 2007; Miller & Dill, 1997) This model 
hypothesizes the protein to be an assembly of conformations existing in equilibrium with 
different population distributions. Therefore, an approaching ligand has the opportunity to 
choose the most appropriate conformation and shift the equilibrium accordingly. 
1.5 Computer-Aided Drug Design 
Computer-aided drug design (CADD) is utilized to illustrate the application of 
molecular modeling methods and computational chemistry to drug design. Escalation of 
computational influence enabled CADD to study more complex biomolecular systems and 
to define, develop and apply more physically accurate models. 
1.5.1 Motivation. Employing experimental methods such as X-ray crystallography 
or NMR solvation techniques to atomically resolve ligand bound complexes at an atomic 
level is extremely time-consuming and laborious and therefore limits their applicability in 
drug design. With that said and done, virtual docking and in-silico screening provides rapid 
and relatively accurate resolution for rationalization and visualization. 
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1.5.2 Protein–ligand docking. The most economical and relatively fast 
computational tool used for in-silico prediction of binding modes and affinities is 
molecular docking (Sousa et al., 2013). In the contemporary drug discovery process, 
protein–ligand docking (a sub-category of molecular docking) signifies a particularly 
essential methodology. (S.-Y. Huang & Zou, 2010; Manly, Chandrasekhar, Ochterski, 
Hammer, & Warfield, 2008; Sousa et al., 2013) Protein-ligand docking is utilized to 
virtually-screen large libraries of prospective ligands and identify the lead compounds 
(Sergio, Nuno, Pedro, & Maria Joao, 2010). Consequently, over the past 20 years, protein–
ligand docking played an active role in pharmaceutical research. There is a great assortment 
of docking software packages available for academic and commercial use. Well-known 
among them are AutoDock (G. Jones, Willett, Glen, Leach, & Taylor, 1997; Morris et al., 
2009), DOCK (Ewing, Makino, Skillman, & Kuntz, 2001; S. Mukherjee, Balius, & Rizzo, 
2010), FlexX (Rarey, Kramer, Lengauer, & Klebe, 1996), Glide (Friesner et al., 2006) and 
GOLD (G. Jones et al., 1997). 
There are two essential components in protein–ligand docking: (i) the search 
algorithm; searches for good binding poses of the ligand with respect to the receptor in the 
binding pocket (ii) the scoring function; estimates the binding affinity of the generated 
binding poses, ranks them, and identifies the most favorable binding pose(s) of the ligand 
with respect to the receptor in the binding pocket. (Du et al., 2016) 
The search algorithms have evolved with the protein-ligand binding mechanisms; 
from the completely rigid-body methods to the flexible ligand-rigid protein, and then to the 
flexible ligand–flexible protein methods. (Sousa et al., 2013) 
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1.5.2.1 Scoring functions. To assess the binding affinity of the ligand towards the 
protein, fast and approximate mathematical methods, scoring functions, are used. (Ewing 
et al., 2001) Scoring functions render a compromise between speed and accuracy based on 
various approximations. Scoring functions are thus particularly suitable for high-
throughput tasks, such as molecular docking, virtual screening, library design, and so on. 
(Liu & Wang, 2015) 
 Many scoring functions are available for protein–ligand docking studies. They are 
classified into three general classes based on how they were devised: the force-field-based, 
the empirical-based, and the knowledge-based scoring functions. (Du et al., 2016) 
1.5.2.1.1 Force-field-based scoring functions. The force-field defines the potential 
energy of the system. In the force-field-based scoring functions, the binding affinities are 
estimated based on force-field parameters (physics-based functions and parameters) 
derived from quantum mechanical calculation of non-covalent interactions (N. Huang, 
Kalyanaraman, Irwin, & Jacobson, 2006). Including the molecular interactions induced by 
binding, changes induced in the solvent and particularly, the entropic effects would give a 
more accurately estimated binding affinity. Explicit treatment of water molecules or 
utilizing implicit solvent models can justify the solvent effect. Implicit solvent models such 
as Poisson–Boltzmann surface area (PB/SA) model (Rocchia et al., 2002; J. Wang, Morin, 
Wang, & Kollman, 2001) and the generalized-Born surface area (GB/SA) model. (G. D. 
Hawkins, C. J. Cramer, & D. G. Truhlar, 1995; Still, Tempczyk, Hawley, & Hendrickson, 
1990)  
ΔGBinding =ΔEvdW +ΔEElectrostatic + ΔEH-bond + ΔGDe-solvation     (1.4) 
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1.5.2.2 Empirical scoring functions. Empirical scoring functions utilize either 
machine learning methods or regression to parameterize the interactions as favorable or 
unfavorable (penalty) energy terms. (Eldridge, Murray, Auton, Paolini, & Mee, 1997; 
Grinter & Zou, 2014) These energy terms include contributions from hydrophilic contacts, 
hydrophobic contacts, electrostatic and van der Waals energies, number of hydrogen 
bonds, number of rotatable bonds that are immobilized upon complex formation, or change 
in solvent accessible surface area (SASA) upon complex formation (Tang, 2010). PLP, (G. 
Verkhivker, Appelt, Freer, & Villafranca, 1995) ChemScore, (Eldridge et al., 1997; 
Murray, Auton, & Eldridge, 1998) X-Score, (R. Wang, Lai, & Wang, 2002) and GlideScore 
(Friesner et al., 2004; Friesner et al., 2006) are popular examples of empirical scoring 
functions. 
1.5.2.2.1 Xtra precision glide score. XP Glide docking function employed in this 
thesis falls under semi-empirical scoring functions which employs H2O de-solvation 
energy terms. It was reported that in XP glide docking, the scoring function reproduced 
experimental binding affinities of 198 ligands on various complexes with known 
experimental binding affinities. Out of the 198 ligands 132 ligands docked agreeably with 
root mean square deviations and average absolute deviations of 1.73 kcal/mol and 1.34 
kcal/mol respectively.(Friesner et al., 2006)  
Glidescore employed by Glide software is formulated as follows 
XP Glidescore = ECoul + EvdW + EBind + EPenalty      (1.5) 
EPenalty = EDe-solvation + ELigand-strain (Friesner et al., 2006)     (1.6) 
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1.5.2.3 Knowledge-based scoring functions. The knowledge-based scoring 
functions assume that the close inter-atomic interactions between the protein and the ligand 
occurring more frequently can be energetically favorable than those anticipated by a 
random distribution and for that reason, contribute favorably to the binding affinity 
(Muegge, 2006). In other words, the statistical potentials are derived from the close 
contacts statistically studied in a training set containing suitable samples.  
       lig prot 
A = ∑ ∑ ωij (r)          (1.7) 
        i     j 
Each scoring function has its own pros and cons and none of them are neither 
accurate nor generally applicable. Therefore, the idea of using a combination of scores 
from multiple scoring functions, consensus scoring strategy, has been introduced to 
improve the accuracy and applicability. (Charifson, Corkery, Murcko, & Walters, 1999; 
S.-Y. Huang, Grinter, & Zou, 2010; G. M. Verkhivker et al., 2000) 
1.5.2.4 Limitations and practical considerations. Most docking methods employ 
various limiting assumptions and oversimplifications, such as rigid binding site, inaccurate 
solvent representation, random probability distribution functions used in conformational 
searches etc. Many virtual screening studies identified a high percentage of false positives 
because of these often-necessary simplifications and inherently inaccurate 
implementations. The utility of docking studies conducted to identify novel potent ligands 
are limited by the rigid depiction of the ligand binding site (neither side-chain nor backbone 
flexibility) as the ligand may bind to the protein by an induced fit mechanism. This 
unsophisticated oversimplification is ignoring certain important energetic modifications 
induced by potential structural changes usually observed in the ligand binding process. 
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Additionally, a rigid-binding site does not account for enthalpy-entropy compensation 
(discussed in Section 1.2.2). 
In docking, implicit solvent representations are used. Docking methods ignore the 
critical role of bound water molecules, accounting to the lack of explicit solvent 
representation. This misrepresentation might lead to inaccurate prediction of the binding 
pose. In these cases, including explicit waters at the binding site might achieve more 
accurate docking predictions. Accurate binding affinity estimations can be achieved by 
accurate physical representation of solvation and de-solvation effects. 
1.5.3 Binding affinity predictions. One of the most critical and challenging 
components to structure-based CADD is predicting binding affinity. (Ajay & Murcko, 
1995; Gohlke & Klebe, 2002) Predicting accurate binding affinity is essential to various 
applications including identification of native binding mode using molecular docking, 
identification of lead compounds by virtual screening of ligand libraries, and increasing 
target specificity and enhancing binding affinity for lead optimization. (Kitchen, Decornez, 
Furr, & Bajorath, 2004; Lyne, 2002; Shoichet, 2004) Even though first-principle methods 
such as free energy perturbation (FEP), (Kollman, 1993) linear interaction energy (LIE), 
(Hansson, Marelius, & Åqvist, 1998) and MM-PBSA/GBSA (P. A. Kollman et al., 2000) 
have gone through significant developments to predict accurate binding affinity (Beveridge 
& DiCapua, 1989; Hansson et al., 1998; P. A. Kollman et al., 2000), fast and relatively 




1.5.3.1 Free energy calculations. Principles of statistical thermodynamics are 
utilized in protein-ligand binding free energy calculations. These are extensive 
computational simulations (Molecular Dynamics or Monte Carlo) based calculations and 
require computational efforts of higher magnitude by several orders than the traditional 
scoring functions. As a reward for the highly intensive computation, the results of free 
energy calculations ought to be reliable and almost quantitative.  
The free energy calculations carry an advantage over the faster scoring functions 
by including both the energetic (solvation energy and potential energy) and entropic 
(solvent effects and flexibility/dynamics of both protein and ligand) contributions. And the 
free energy calculations do not require case-by-case parameter fitting. (de Ruiter & 
Oostenbrink, 2011; S. Thomas & Andreas, 2010) 
The three main types of free energy calculations: the alchemical calculation, the 
path sampling, and the endpoint methods. Many factors like the length of the simulation, 
whether the absolute or relative binding free energy was calculated and whether an implicit 












1.5.3.1.1 Endpoint methods. The endpoint method calculates the binding free 
energies of the unbound state and bound state only. The intermediates stages are not 
considered. It is to be noted that endpoint method could be the efficient method of all three. 
The most endpoint methods applied to the binding free energy calculations, are molecular 
mechanics generalized Born surface area (MM-GBSA) and molecular mechanics Poisson-
Boltzmann surface area (MM-PBSA). (P. A. Kollman et al., 2000; Srinivasan, Cheatham, 
Cieplak, Kollman, & Case, 1998) In the GB/SA and PB/SA method, the binding free 
energy is calculated as:  
∆GBind = GC – (GP+GL)         (1.4) 
Where GC is the free energy of the protein-ligand complex’s molecular system, GP 
is the free energy of the protein molecular system and GL is the free energy of the ligand 
molecular system. (Joseph M. Hayes, 2012) The free energy of each system is defined as: 
G = EMM + GSolv – TS          (1.5) 
Where EMM is the total molecular mechanics energy of molecular system in the gas 
phase, GSolv is a solvation free energy of the molecular system in solvent and T is 
temperature and S is the entropy of the molecular system (Joseph M. Hayes, 2012) (as 
explained in section 1.2.1.2). The total molecular mechanics energy of molecular system 
is defined as the sum total of energies contributed by covalent interactions (EBonded), 
electrostatic interactions (EElec) and van der Waals interactions (EVdW). (Joseph M. Hayes, 
2012) 
EMM = EBonded + EElec + EVdW          (1.6) 
The molecular mechanics energy of the system is computed by the molecular 
mechanics energy function known as force field. The solvation free energy constitutes 
 
15 
polar (GGB/PB) and non-polar (GSASA) contributions from the solvent. (Joseph M. Hayes, 
2012) 
GSolv = GGB/PB + GSASA          (1.7) 
The polar component is interpreted by the generalized Born (GB)/Poisson or 
Poisson-Boltzmann (PB) model. The non-polar component is considered to be proportional 
to solvent-accessible surface area (SASA). (Joseph M. Hayes, 2012) 
GB/SA and PB/SA methods are more relevant to ranking of ligand binding 
affinities rather than to predict absolute binding free energies owing to its intrinsic 
approximations. Although, incorporating solute entropy (Foloppe & Hubbard, 2006) and 
solvent effects (Singh & Warshel, 2010) in binding affinity calculations is challenging, 
many studies applied PB/SA and GB/SA methods successfully and have generated some 
promising results. (Joseph M. Hayes, 2012) As MM-GBSA calculation ranges between 
their intermediate position between the empirical scoring and rigorous alchemical 
calculation methods in terms of both accuracy and computational intensity, PB/SA and 
GB/SA methods could be useful for post-processing of the docked structures or be used to 
rationalize the observed differences. (Genheden & Ryde, 2015)  
1.5.3.1.2 Limitations and practical considerations. Although empirical scoring 
functions came a long way, there is still room for significant improvement in both 
applicability and accuracy. Accurate ranking of binding poses based on the relative 
affinities is still a challenge. The inability of the scoring functions used in virtual-screening 
studies to characterize the accurate binding nature constitutes as another limitation, 
especially the unrepresented systems of the training sets. Considering a best-case scenario 
where the docking method successfully predicted an accurate binding pose, the rigidity of 
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the protein might hinder the accuracy of the scoring function and generate false positives 
and false negatives. Under the assumption of correct binding pose prediction, this 
limitation could be circumvented by estimating binding affinities by utilizing first-principle 
methods.  
1.6 Molecular Dynamics Simulations 
As mentioned in section 1.5.2.4 the rigidity of protein is a limitation to the CADD 
and needs to be dealt with. However, to deal with this and develop a computational 
technique that can simulate protein dynamics, highly complicated and computationally 
demanding quantum-mechanics (QM) based calculations pertaining large molecular 
systems are required.   
Molecular dynamics (MD) simulations, first developed in the late 1970’s 
(McCammon, Gelin, & Karplus, 1977), simulate atomic motions utilizing Newtonian 
physics based on unassuming approximations thereby reducing the computational 
intricacy.  
Initially, NMR spectroscopic, X-ray crystallographic, or homology-modeling data, 
in that preferential order, is utilized to formulate a molecular model of the molecular 
system. A potential energy estimation is made by formulating the forces acting on every 
atom of the system (Cornell et al., 1995). In short, covalent and non-covalent interactions 
of the system. Simple virtual springs, were utilized to model chemical bonds; sinusoidal 
function that approximates the energy differences between eclipsed and staggered 
conformations was utilized to model dihedral angles and atomic angles. The Lennard-Jones 
6- 12 potential (J. E. Jones, 1924) was utilized to model van der Waals interactions and 
Coulomb’s law for electrostatic interactions. These energetic terms need to be 
 
17 
parameterized to fit QM calculations and experimental data to be able to simulate the 
natural dynamics of the molecules. All these parameters are collectively known as a ‘force-
field’. Because these parameters define the forces that control and effect the dynamics 
simulation. Commonly known MD simulation force-fields are AMBER (Cornell et al., 
1995; J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman, & D. A. Case, 2004), 
CHARMM (Brooks et al., 1983), GROMOS (Christen et al., 2005) , NAMD (Kale et al., 
1999; Phillips et al., 2005) etc. They differ only in the approach of parameterization.  
Once the force-field has been defined, all atoms of the system are stimulated 
according to Newton’s laws of motion. The molecular system will be simulated often by 
only 1-2 quadrillionths of a second, and this process is repeated, typically for a million 
times. As it is apparent that MD simulations require so many calculations, computer 
clusters or super-computers utilizing multiple processors in parallel are used to conduct 
them. One of the applications of MD simulations is validation of a force-field by comparing 
simulated data with experimental data (van Gunsteren, Dolenc, & Mark, 2008).  
Many properties such as the time evolved root-mean-squared coordinate deviation 
(RMSD) to the initial structure, distance time series, angle time series, energy time series, 
H-bond time series etc., are used to characterize these MD simulation trajectories. 
However, extracting and evaluating some properties such as entropies and enthalpies can 
be time-consuming. Moreover, interpretation of these properties and the intrinsic 
relationships between the molecular configurations could be lost in the complexity of the 
data. To simplify this complexity a data mining tool called clustering analysis is used. 
(Karpen, Tobias, & Brooks, 1993; Shao, Tanner, Thompson, & Cheatham, 2007; Shenkin 
& McDonald, 1994) Clustering analysis groups MD simulated conformations based on 
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homogenous structures. (Barnard & Downs, 1992) Every conformation is divided into 
various groups known as clusters based on relative similarity. Each cluster has MD 
simulated conformations that resemble each other or are distinct from every other cluster. 
(Hartigan & Wong, 1979) 
Regardless of the flaws in conformational sampling and current force fields, the 
insights offered by MD simulations into protein dynamics play essential roles in CADD. 
In the drug-binding process, the small molecule (drug) does not find a distinct rigid 
structure, rather a large dynamic molecular system in constant motion. MD simulations 
succeed where NMR, X-ray crystallography, and homology modeling generated rigid-
receptor models fail to reproduce the dynamic molecular recognition and drug binding 
processes. Whether it’s a lock-key model, where the drug might bind to a rigid binding 
pocket and the receptor dynamics are limited (E. Fischer, 1894) or a more common 
induced-fit model, where the drug binds only to a handful of conformations sampled by its 
dynamic receptor (Kumar, Ma, Tsai, Wolfson, & Nussinov, 1999; Ma et al., 1999; Ma, 
Shatsky, Wolfson, & Nussinov, 2002; C. J. Tsai, S. Kumar, B. Ma, & R. Nussinov, 1999) 
or it’s inducing more conformational changes that cannot be sampled in its absence 




Chapter 2  
CADD in Boron Therapeutics 
2.1 Abstract 
Tavaborole, the recently approved topological anti-fungal drug, inhibits leucyl 
tRNA synthetase by bonding covalently and hinders protein synthesis. The benzo-boroxole 
pharmacophore of tavaborole is responsible for its unique activity. With proper 
understanding of the tavaborole binding site, designing a molecule to enhance the binding 
affinity of tavaborole analogs should be quite achievable. The 3D crystal structure of fungal 
leucyl tRNA synthetase has not been solved yet. So, a theoretical 3D model of fungal leucyl 
tRNA synthetase has been generated and a combinatorial library has been generated by 
optimizing libraries of already synthesized drugs designed based on biological activity of 
amino-benzo-boroxoles on anti-cancer cell lines using the previously generated 3D model. 
The synthesized drug library mimics the activity of bortezomib. However, the 
pharmacophore benzo-boroxole would be more relevant to tavaborole rather than to 
bortezomib with a boronic acid pharmacophore. This study theoretically proposes 
molecules with prospective improved affinity towards fungal leucyl tRNA synthetase. To 
improve the selectivity of these molecules a theoretical 3D model of human leucyl tRNA 
synthetase has been generated and the hits from fungal leucyl tRNA synthetase are 





The element boron is not very commonly found in living bodies however, it has 
been gaining a lot of attention recently, accounting to its potential for new therapeutic 
biological activity and drug design. The attention may be new but utilization of boron 
containing compounds started long ago with boric acid and borax.(Tibi, 2006) Although 
boron-chemistry started with inorganic boric acid compounds and borax, it has now 
progressed to boron based organic chemistry (Baker et al., 2009; Baker, Tomsho, & 
Benkovic, 2011; Das et al., 2013; Hernandez et al., 2013) and has been approved as an 
anticancer (bortezomib (Adams et al., 1998)) and antifungal (tavaborole (Leśnikowski, 
2016; Rock et al., 2007)) agents in 2003 and 2014 respectively. 
2.3 Tavaborole 
Tavaborole (5-fluoro-1,3-dihydro-1-2,1-benzoxaborole/AN2690) is one of the 
most effective treatment against onychomycosis. Tavaborole is a topically acting, broad-
spectrum antifungal agent. (Baker et al., 2006; A. K. Gupta & Simpson, 2012) 
2.3.1 Onychomycosis. A fungal infection of the nail plate or the nail bed is known 
as onychomycosis. (Seebacher et al., 2007; J. Thomas et al., 2010) 80-90% of the 
documented onychomycosis cases are assessed to be caused by the dermatophytes 
Trichophyton rubrum and Trichophyton mentagrophytes. (J. Thomas et al., 2010) When 
left untreated, the nail plate gradually deteriorates and separates from the nail bed. It has 
been reported that the incidence rate of onychomycosis is ∼10% of the worldwide 
population, ∼20% for the >60 years old population and ∼50% for people aged >70 years. 
(Elewski, 2000; J. Thomas et al., 2010; Westerberg & Voyack, 2013) While 
onychomycosis is not life threatening, it can lead to the cause of lesions in other regions 
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and can have grave consequences in combination with various other conditions like 
diabetes and contribute to poor quality of life. (Drake et al., 1999; A. P. Gupta, Verma, & 
Ikram, 2000) There is always a chance of infecting others and becoming a public health 
hazard.  
2.3.2 Mechanism of action. The mechanism of action of the fungicidal tavaborole 
has been explained by crystallographic, biochemical, and chemical studies. Tavaborole has 
been demonstrated to be effective against Trichophyton rubrum and Trichophyton 
mentagrophytes by targeting their leucyl tRNA synthetase (LeuRS). (Adamczyk-Woźniak, 
Komarovska-Porokhnyavets, Misterkiewicz, Novikov, & Sporzyński, 2012; Baker et al., 
2006; Rock et al., 2007) LeuRS belongs to the class of aminoacyl-tRNA synthetases, a 
class of enzymes crucial for protein synthesis. 
2.4 Hypothesis 
Pathi et al., reported cell viability assays for synthesized amino-benzo-boroxoles 
(tavaborole analogs) and in-vitro IC50 for compounds with promising anti-cancer activity 
(Suman, Patel, Kasibotla, Solano, & Jonnalagadda, 2015) mimicking boronic acid 
containing bortezomib and ixazomib. However, the pharmacophore, benzo-boroxole is 
more similar to tavaborole. So, the goal of this study is to optimize anti-fungal activity of 
tavaborole analogs reported in table 1. This study attempts to optimize the antifungal 





Table 1  
Biological activity of benzo-boroxoles in anticancer cell-lines. 
Structure 
MIA PaCa-2 MDA-MB-231 
% Cell Viability  
IC50 
% Cell Viability 
IC50 
50 µM 12.5 µM 50 µM 12.5 µM 
 
28.6 28.2 8.3 44.8 44.3 11.5 
 
61.0 83.0  123.2 118.7  
 




2.5 Role of LeuRS in Protein Synthesis 
Major steps of protein synthesis are initiation, elongation, termination and folding. 
Amino-acylation reaction triggers the protein synthesis, followed by elongation of protein 
chain by formation of several peptide bonds and elongating the protein. The elongation is 
then terminated by the termination codon of mRNA and the newly synthesized protein is 
released which is consequently folded into its tertiary structure. (Banik & Nandi, 2013) 
2.5.1 Amino-acylation reaction. The amino-acylation reaction binds an amino-
acid with the transfer RNA. These amino-acids are attached to the transfer RNA (tRNA) 
by a class of enzymes called aminoacyl tRNA synthetases. The tRNA then transfers those 
amino acids onto the protein. (Ibba & Söll, 2000) There are two classes of aminoacyl tRNA 
synthetases. The difference between the classes being the transfer of the amino acid onto 
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2’-hydroxyl group in class I and onto 3’-hydroxyl group in class II. Most cells have at least 
20 different aminoacyl tRNA synthetases, one for each essential amino acid. (Khan et al., 
2011) However, many cells have additional aminoacyl tRNA synthetases. LeuRS belongs 
class II of the aminoacyl tRNA synthetases. 
The aminoacylation of tRNA is a 2-step process: (i) the formation of aminoacyl 
adenylate from the amino acid in question triggers the 2nd step. The 𝛼-carboxylate group 
of the amino acid and the 𝛼-phosphate group of ATP forms aminoacyl adenylate, a mixed 
anhydride, in the presence of divalent magnesium (Mg2+) ions and releases pyrophosphate. 










(ii) The amino acid in aminoacyl adenylate is transferred onto the 2′ or 3′ sugar 
hydroxyl group of the 3′-terminal adenosine nucleotide of the tRNA. (Figure 4) The 
accuracy of this process is very essential in ensuring the fidelity of the genetic code which 
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would otherwise lead to the synthesis of nonsensical proteins (Hong et al., 1996).  To 
ensure this accuracy, most of the aminoacyl tRNA synthetases have an editing site to rectify 
an incorrectly aminoacylated tRNA (Schimmel & Schmidt, 1995). LeuRS has same 
proofreading mechanism. The synthetic and editing domains of LeuRS are separated by 









Many factors affect the selectivity for amino-acids; including amino-acid size, 
shape along with presence of an editing domain. (Guo & Schimmel, 2013) Concluding that 
aminoacyl tRNA synthetases are crucial for protein synthesis and cellular viability.  
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Tavaborole selectively binds to the editing domain of LeuRS. Tavaborole slowly 
and strongly binds to the binding site of leucine and renders the whole protein useless. 
(Figure 5) This subsequently stops protein synthesis or leads to synthesis of proteins with 
incorrect amino acid sequence. Eventually leading to apoptosis one way or the other. 
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(Lincecum et al., 2003) Rock et al reported that based on the X-ray crystallographic studies 
on LeuRS of Thermus thermophiles complexed with tavaborole, a tRNA-tavaborole spiro-
ester adduct was formed by sp2 hybridized boron from the boroxole ring and the two 2’, 
3’-hydroxyl groups on the terminal adenosine where boron is sp3 hybridized with 
tetrahedral structure. The two hydroxyl groups which are essential to the amino-acylation 
reaction. This adduct formation is further stabilized by two H-bonds with threonine peptide 
and H2O molecule. (Rock et al., 2007) This process is commonly referred to as the 
oxaborole tRNA trapping (OBORT) mechanism. (Baker et al., 2011) This stable complex 
has a half-life of ~7 hours at the active site. (Rock et al., 2007) 
2.6.1 Structure-activity relationships (SAR) of benzo-boroxoles. Based on the 
SAR studies the 5-membered boroxole ring in which the boronic acid is embedded is 
critical for the therapeutic activity of the benzo-boroxoles. Comparative biochemical 
assays indicated substantial loss of antifungal activity with 6-membered ring and acyclic 





Figure 6. Structure of Tavaborole. 
 
This unusual activity of the boroxole ring is fascinating, since the reaction 
coefficient of the very well-known boric, boronic and borinic ester formation with alcohols 
in aqueous solution by the corresponding acid is pKa dependent not the structure. 
(Martínez-Aguirre, Villamil-Ramos, Guerrero-Alvarez, & Yatsimirsky, 2013) Benzo-
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boroxoles certainly have more pKa than acyclic boronic acids. (Yamaguchi et al., 2012) 
This however, cannot be correlated with disproportional increase of antifungal activity 
when compared with their corresponding acyclic boronic acids. Although in the absence 
of LeuRS, both benzo-boroxoles and acyclic boronic acids promptly forms esters 
interchangeably in neutral aqueous medium with mono-alcoholic and di-alcoholic 
compounds due to their obviously low association constants. (Martínez-Aguirre et al., 
2013; Tomsho & Benkovic, 2012) Therefore, it is presumed that the hydrolysis of the 
boronic ester that usually occurs in the aqueous solution is prevented by the hydrophobic 
binding site of the editing domain in LeuRS. Thus the benzo-boroxole-LeuRS complex is 
selectively stabilized. (Baker et al., 2006)  
2.7 Computational Approach 
The goal of the study is to suggest modifications to the given library so as to 
optimize the fungicidal activity. The approach would be to  
(i) validate the protein and ligand model,  
(ii) virtually dock the ligands at the binding site and analyze the corresponding 
interactions,  
(iii) identify the modification site,  
(iv) enumerate the fragment library at individual modification sites and rank the 
fragments with respect to the fragment site,  
(v) enumerate fragments at all sites and score the final modifications. 
2.7.1 Challenges and assumptions. As mentioned in section 2.1.1.1 80-90% of 
onychomycosis is caused by Trichophyton mentagrophytes and Trichophyton rubrum. 
However, the 3D structure of LeuRS of neither is available in the protein data bank.  
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2.7.1.1 Homology modeling. A theoretical 3D structure of the Trichophyton 
rubrum has been generated by Prime (Jacobson, Friesner, Xiang, & Honig, 2002; Jacobson 
et al., 2004) (Schrodinger) software utilizing its amino-acid sequence from UniProt 
Consortium© (Magrane & Consortium, 2011)  and the template, PDB ID: 2V0G from PDB 
(Berman et al., 2000). 2V0G is the 3D structure of LeuRS from Thermus Thermophilus, a 
Gram negative eubacterium, complexed with tRNA and characterizing formation of spiro-





Figure 7. 3D representation of homology modeled fungal LeuRS complexed with tRNA 




The Glide (Friesner et al., 2004; Friesner et al., 2006; Halgren et al., 2004) software 
utilized to do molecular docking can form one covalent bond (covalent docking (Zhu et al., 
2014)) with the amino-acid residues but the software has not been developed to conduct 
two subsequent covalent bonds formation with nucleic acids as observed with the spiro-
ester formation. 
To overcome this challenge only the approachability of the ligand is studied. As the 
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covalent bond formation is a fast and exothermic reaction which facilitates subsequent 





Figure 8. tRNA - Tavaborole complex adjusted from covalently bonded complex to non-




2.8 Comparison with Human LeuRS – Selectivity 
Tavaborole is a topologically acting drug. Systemic activity can be induced when 
the ligands have preferential activity towards fungal LeuRS rather than human LeuRS. 
With this goal, the binding sites of both fungal and human LeuRS with tavaborole are 




Figure 9. 3D representation of superimposed structures of homology modeled fungal and 




As mentioned in section 2.1.1.3 the SAR studies suggest the binding site of the 
fungal LeuRS and tavaborole to be hydrophobic. This is explained by comparison of the 




Table 2  
Homology, identity and similarity statistics of human LeuRS compared to fungal LeuRS. 
 Human LeuRS 
Homology 45 % 
Identity 34 % 





Figure 10. Sequence alignment of fungal LeuRS and human LeuRS; residues interacting 
with tavaborole at the binding site of fungal LeuRS are depicted in yellow and human 
LeuRS in blue. Residues depicted in green are common in both fungal and human LeuRS-
tavaborole binding site. 
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The highlighted cells in the table 3 indicate amino-acids that might be responsible 
for high hydrophobicity at the binding site of tavaborole with fungal LeuRS compared to 




Table 3  
List of the interacting residues (highlighted in figure 10) at the binding site of fungal LeuRS 
compared with residues interacting at the binding site of human LeuRS; highlighted cells 
indicate residues that might be responsible for high hydrophobicity of tavaborole binding 



























2.9.1 Inherent inaccuracies in experimental data. As mentioned in section 
2.6.1.1 a theoretical 3D structure of LeuRS of Trichophyton rubrum has been generated by 
homology modeling using the template, PDB ID: 2V0G from PDB (Berman et al., 2000). 
The Protein Data Bank (PDB) has a comprehensive collection of X-ray and NMR solved 
biomolecular structures. (Westbrook et al., 2003) However, the experimental conditions 
like pH, temperature, salt concentrations etc., induced to crystallize the protein might differ 
from the actual physiological conditions. The minimal resolution of the model might result 
in inaccuracies on an atomic level. (Tang, 2010) For these reasons, this structure needs to 
be prepared to increase the accuracy and structural correctness of the 3D protein model. 
Schrodinger Maestro’s protein preparation wizard was used to prepare the structure, 
optimize the H-bond network and minimize the potential energy of the protein model. 
("Maestro© 2014 Schrödinger, LLC. Manuals,") 
2.9.2 Validation. The protein-ligand model, 3D structure generated from 
homology modelling in complex with tavaborole, was validated by conducting molecular 
docking studies on compounds with reported inhibitory activity against cytoplasmic LeuRS 






Table 4  
List of IC50 values of compounds structurally similar to tavaborole and their corresponding 
docking scores and MM-GBSA values against fungal LeuRS. The highlighted cells depicts 
activity of tavaborole. 



































Figure 11.  Graph plotting Docking score of the molecules listed in table 4 vs binding 






















Figure 12. Graph plotting MM-GBSA values of the molecules listed in table 4 vs binding 




The XP docking score generated by Glide and MM-GBSA free binding energy 
generated by Prime are used to validate the binding affinities. The docking score of the 
active compound is lowest when compared with other structurally similar compounds 
(indicated in Figure 6) however, the MM-GBSA binding energies show that the active 
compound has highest binding affinity when compared with the same (indicated in Figure 
7). So, MM-GBSA free binding energy is used to validate the relative affinity of the 
ligands. 
2.9.3 Screening the given library. The given libraries are screened based on the 
binding pose; extra precision glide docking is used to generate a binding pose for each 
ligand. The generated binding pose is then compared by super imposing with the binding 
pose of tavaborole. The ligands with binding poses that does not facilitate the formation of 
the spiro-adduct (boronic ester) are screened out. Since covalent bond formation between 
the boroxole of the ligands and the di-hydroxyl groups of the ribose from tRNA is essential 





















boroxole with the boroxole of tavaborole is eliminated.  
2.9.3.1 Ligand library 1 (LL1). In the tables 5, 6 and 7 listed below the 
highlighted cells have structures that successfully reproduced the binding pose that 





Table 5  
List of the docked molecules of ligand library 1 (LL1) and their binding pose in complex 
with fungal LeuRS. The highlighted cells indicate molecules with appropriate binding pose. 
LL1_1 Binding Pose 
  
LL1_2 Binding Pose 
  




Table 5 (continued) 
LL1_5 Binding Pose 
 
 
LL1_6 Binding Pose 
  
LL1_7 Binding Pose 
 
 
LL1_8 Binding Pose 
  





Table 5 (continued) 
LL1_10 Binding Pose 
 
 
LL1_12 Binding Pose 
 
 
LL1_13 Binding Pose 
  












Table 6  
List of the docked molecules of ligand library 2 (LL2) and their binding pose in complex 
with fungal LeuRS. The highlighted cells indicate molecules with appropriate binding pose. 
LL2_1 Binding Pose 
 
 
LL2_2 Binding Pose 
  
LL2_3 Binding Pose 
 
 






Table 6 (continued) 
LL2_5 Binding Pose 
 
 









Table 7  
List of the docked molecules of ligand library 3 (LL3) and their binding pose in complex 
with fungal LeuRS. The highlighted cells indicate molecules with appropriate binding pose. 




Table 7 (continued) 
LL3_2 Binding Pose 
 
 
LL3_3 Binding Pose 
 
 
LL3_4 Binding Pose 
 
 





Table 7 (continued) 
LL3_6 Binding Pose 
 
 
LL3_7 Binding Pose 
 
 
LL3_8 Binding Pose 
  
LL3_9 Binding Pose 
  





2.9.4 Binding site analysis and enumeration. The binding site analysis provided 
by maestro is used to analyze and define prospective R-group positions to optimize the 
non-covalent interactions without disrupting the covalent bond formation. This binding site 
analysis indicates voids in the protein-ligand complex at the binding site. (i) Defining an 
R-group at each of these voids would optimize the affinity of the ligand without disrupting 
the covalent bond formation. Once these sites have been identified, (ii) the fragment library 
provided by maestro is used to enumerate R-groups at those defined positions. (iii) The 
resulting ligand library is docked into the binding site. (iv) The resulting docked binding 
poses are screened based on their comparability with binding pose of tavaborole. (v) Free 
energy binding affinities of these screened molecules (MM-GBSA ∆GBind) are calculated. 
5 best fragments with high affinity binding poses are selected. After filtering out top 
affinity generating fragments at all predefined R-group sites, (vi) these fragments are then 
enumerated at their respective enumeration site. (vii) Once the generated library is docked 
and the incomparable binding poses are filtered out, a final active ligand library is 
generated. (viii) MM-GBSA ∆GBind is then calculated for this final ligand library. 
To achieve selectivity over human LeuRS, (ix) this final ligand library is docked 
into the binding site of the human LeuRS-tavaborole complex, which has been homology 
modelled using the same template used for generating fungal LeuRS-tavaborole complex. 
(x) Then a maximum of six best ligands displaying major affinity difference between 
fungal and human LeuRS and obviously favorable towards fungal LeuRS are screened. 
(Listed in results (2.9.5) section for every active ligand listed in tables 5, 6 and 7. For those 
ligands which gave no positive hits against human LeuRS, 6 best ligands with high MM-




2.9.5.1 Modifications on LL1_5. As mentioned in section 2.3.2 (i) Table 8 
depicts the surfaces generated by binding site analysis and the voids represented by these 
surfaces. And these voids can accommodate a new R-group that optimize the affinity 
without disrupting the binding pose. All the prospective sites for modification are 




Table 8  
The surfaces generated by binding site analysis at the LeuRS-LL1_5 binding site and 
arrows point to modification site of R0, R1, R2, R3 and R4.  
R0 R1 R2, R3 and R4 









Once the modification sites have been identified, these sites have been enumerated 
with fragment library provided by Schrodinger followed by steps (iii), (iv) and (v) (listed 
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Table 9  
Hits from single site enumeration at R0 of LL1_5. 














Table 10  
Hits from single site enumeration at R1 of LL1_5. 

















Table 11  
Hits from single site enumeration at R2 of LL1_5. 






Table 12  
Hits from single site enumeration at R3 of LL1_5. 

















Table 13  
Hits from single site enumeration at R4 of LL1_5. 








Once the top fragments have been identified, the steps (vii) (viii) (ix) and (x) (as listed in 























































































































































































































































































































































































































Table 15  
The surfaces generated by binding site analysis at the LeuRS-LL1_6 binding site and 
arrows point to modification site of R0, R1, R2, and R3.  
R0 R1 R2 R3 









Table 16  
Hits from single site enumeration at R0 of LL1_6. 






Table 17  
Hits from single site enumeration at R1 of LL1_6. 

















Table 17 (continued) 













Table 18  
Hits from single site enumeration at R2 of LL1_6. 



















Table 18 (continued) 

















Table 18 (continued) 






































































































































































































































































































































































































Table 20  
The surfaces generated by binding site analysis at the LeuRS-LL1_7 binding site and 
arrows point to modification site of R0, R1 and R2.  










Table 21  
Hits from single site enumeration at R0 of LL1_7. 









Table 21 (continued) 
















Table 21 (continued) 










Table 22  
Hits from single site enumeration at R1 of LL1_7. 









Table 22 (continued) 














Table 23  
Hits from single site enumeration at R2 of LL1_7. 






Table 23 (continued) 

















Table 24  
Hits from enumeration at all modification sites of LL1_7. 











Table 24 (continued) 















Table 25  
The surfaces generated by binding site analysis at the LeuRS-LL1_9 binding site and 
arrows point to modification site of R0, R1, R2 and R3.  










Table 26  
Hits from single site enumeration at R0 of LL1_9. 






















Table 27  
Hits from single site enumeration at R1 of LL1_9. 















Table 27 (continued) 






Table 28  
Hits from single site enumeration at R2 of LL1_9. 











Table 28 (continued) 






Table 29  
Hits from single site enumeration at R3 of LL1_9. 











Table 29 (continued) 













Table 29 (continued) 


































































































































































































































































































































































































































Table 31  
The surfaces generated by binding site analysis at the LeuRS-LL1_10 binding site and 
arrows point to modification site of R1 and 2D structure of LL1_10 illustrating its 







Table 32  
Hits from single site enumeration at R1 of LL1_10 and comparison with human LeuRS. 
 MM-GBSA ∆GBind Docking Score 
Structure Fungal Human Difference Fungal Human Diff 
 
-84.665 -38.779 -45.886 -5.589 -4.29 -1.299 
 
-83.961 -34.274 -49.687 -5.264 -4.651 -0.613 
 





Table 32 (continued) 
 MM-GBSA ∆GBind Docking Score 
Structure Fungal Human Diff Fungal Human Diff 
 
-77.14 -24.27 -52.87 -4.594 -5.939 1.345 
 
-68.825 -25.042 -43.783 -4.469 -4.427 -0.042 
 









Table 33  
The surfaces generated by binding site analysis at the LeuRS-LL1_12 binding site and 
arrows point to modification site of R0, R1 and R2.  










Table 34  
Hits from single site enumeration at R0 of LL1_12. 








Table 35  
Hits from single site enumeration at R1 of LL1_12. 

















Table 35 (continued) 












Table 36  
Hits from single site enumeration at R2 of LL1_12. 







Table 36 (continued) 

















Table 36 (continued) 










Table 37  
Hits from enumeration at all modification sites of LL1_12. 































Table 38  
The surfaces generated by binding site analysis at the LeuRS-LL1_13 binding site and 
arrows point to modification site of R0, R1, R2 and R3.  
R0 R1 R2 R3 









Table 39  
Hits from single site enumeration at R1 of LL1_13. 







Table 39 (continued) 













Table 39 (continued) 













Table 39 (continued) 












Table 40  
Hits from single site enumeration at R2 of LL1_13. 













Table 40 (continued) 













Table 40 (continued) 


































































































































































































































































































































































































Table 42  
The surfaces generated by binding site analysis at the LeuRS-LL1_14 binding site and 











Table 43  
Hits from single site enumeration at R1 of LL1_14. 









Table 43 (continued) 
















Table 44  
The surfaces generated by binding site analysis at the LeuRS-LL2_1 binding site and 
arrows point to modification site of R0, R1, R2, R3, R4 and R5.  
R0 R1, R2 R3, R4 and R5 









Table 45  
Hits from single site enumeration at R0 of LL2_1. 









Table 45 (continued) 








Table 46  
Hits from single site enumeration at R1 of LL2_1. 












Table 47  
Hits from single site enumeration at R2 of LL2_1. 










Table 48  
Hits from single site enumeration at R3 of LL2_1. 











Table 49  
Hits from single site enumeration at R4 of LL2_1. 








Table 50  
Hits from single site enumeration at R5 of LL2_1. 



































































































































































































































































































































































































































Table 52  
The surfaces generated by binding site analysis at the LeuRS-LL2_2 binding site and 
arrows point to modification site of R0, R1, R2 and R3.  










Table 53  
Hits from single site enumeration at R0 of LL2_2. 






Table 53 (continued) 

















Table 53 (continued) 






Table 54  
Hits from single site enumeration at R1 of LL2_2. 











Table 54 (continued) 








Table 55  
Hits from single site enumeration at R2 of LL2_2. 









Table 55 (continued) 










Table 56  
Hits from single site enumeration at R3 of LL2_2. 








Table 56 (continued) 


































































































































































































































































































































































































































Table 58  
The surfaces generated by binding site analysis at the LeuRS-LL2_3 binding site and 
arrows point to modification site of R0, R1, R2, R3, R4 and R5.  










Table 59  





















Table 60  
Hits from single site enumeration at R1 of LL2_3. 






Table 61  
Hits from single site enumeration at R2 of LL2_3. 

















Table 62  
Hits from single site enumeration at R3 of LL2_3. 












Table 62 (continued) 








Table 63  
Hits from single site enumeration at R4 of LL2_3. 





















































































































































































































































Table 65  
The surfaces generated by binding site analysis at the LeuRS-LL2_4 binding site and 
arrows point to modification site of R0, R1, R2, R3 and R4.  
R0 R1 and R2 R3 and R4 









Table 66  
Hits from single site enumeration at R0 of LL2_4. 







Table 66 (continued) 










Table 67  
Hits from single site enumeration at R1 of LL2_4. 









Table 67 (continued) 








Table 68  
Hits from single site enumeration at R2 of LL2_4. 











Table 68 (continued) 






Table 69  
Hits from single site enumeration at R3 of LL2_4. 













Table 70  
Hits from single site enumeration at R4 of LL2_4. 
































































































































































































































































































































































































































Table 72  
The surfaces generated by binding site analysis at the LeuRS-LL2_6 binding site and 
arrows point to modification site of R0, R1, R2, R3, R4, R5, R6 and R7.  
R0 R1, R2 and R3 R4, R5, R6 and R7 









Table 73  
Hits from single site enumeration at R0 of LL2_6. 







Table 73 (continued) 












Table 74  
Hits from single site enumeration at R2 of LL2_6. 







Table 74 (continued) 
















Table 75  
Hits from single site enumeration at R3 of LL2_6. 











Table 76  
Hits from single site enumeration at R4 of LL2_6. 







Table 76 (continued) 










Table 77  
Hits from single site enumeration at R6 of LL2_6. 















































































































































































































































Table 79  
The surfaces generated by binding site analysis at the LeuRS-LL3_4 binding site and 
arrows point to modification site of R1, R2, R3, R4 and R5.  
R1 R2 R3 and R4 R5 









Table 80  
Hits from single site enumeration at R1 of LL3_4. 







Table 80 (continued) 






Table 81  
Hits from single site enumeration at R2 of LL3_4. 









Table 82  
Hits from single site enumeration at R3 of LL3_4. 








Table 83  
Hits from single site enumeration at R4 of LL3_4. 












Table 83 (continued) 








Table 84  
Hits from single site enumeration at R5 of LL3_4. 






Table 85  
Hits from enumeration at all modification sites of LL3_4. 








Table 85 (continued) 













Table 85 (continued) 













Table 86  
The surfaces generated by binding site analysis at the LeuRS-LL3_5 binding site and 
arrows point to modification site of R1, R2, R3, R4, R5 and R6.  
R1 R2 and R5 R3 R4 R6 









Table 87  
Hits from single site enumeration at R1 of LL3_5. 







Table 87 (continued) 








Table 88  
Hits from single site enumeration at R2 of LL3_5. 











Hits from single site enumeration at R3 of LL3_5. 










Table 90  
Hits from single site enumeration at R4 of LL3_5. 











Table 91  
Hits from single site enumeration at R5 of LL3_5. 











Table 92  
Hits from single site enumeration at R6 of LL3_5. 










Table 93  
Hits from enumeration at all modification sites of LL3_5. 









Table 93 (continued) 















Table 93 (continued) 













Table 94  
The surfaces generated by binding site analysis at the LeuRS-LL3_6 binding site and 
arrows point to modification site of R1, R2, R3, R4, R5, R6, and R7.  
R1 R2 and R3 R4 and R5 R6 and R7 









Table 95  
Hits from single site enumeration at R1 of LL3_6. 






Table 95 (continued) 








Table 96  
Hits from single site enumeration at R2 of LL3_6. 








Table 97  
Hits from single site enumeration at R3 of LL3_6. 








Table 98  
Hits from single site enumeration at R4 of LL3_6. 









Table 99  
Hits from single site enumeration at R5 of LL3_6. 








Table 100  
Hits from single site enumeration at R6 of LL3_6. 









Table 101  
Hits from single site enumeration at R7 of LL3_6. 








Table 102  

















































Table 103  
The surfaces generated by binding site analysis at the LeuRS-LL3_9 binding site and 
arrows point to modification site of R1, R2, R3, R4 and R5.  
R1 R2 R3, R4, and R5 









Table 104  
Hits from single site enumeration at R1 of LL3_9. 






Table 104 (continued) 








Table 105  
Hits from single site enumeration at R2 of LL3_9. 











Table 105 (continued) 






Table 106  
Hits from single site enumeration at R3 of LL3_9. 








Table 107  
Hits from single site enumeration at R4 of LL3_9. 


















Table 108  
Hits from single site enumeration at R5 of LL3_9. 









Table 108 (continued) 












Table 109  
Hits from enumeration at all modification sites of LL3_9. 








Table 109 (continued) 















Table 109 (continued) 









Chapter 3  
Probing the Binding Pathway of BRACO19 to a Parallel-Stranded Human 
Telomeric G-Quadruplex Using Molecular Dynamics Binding Simulation with 
AMBER DNA OL15 and Ligand GAFF2 Force Fields 
3.1 Abstract 
Human telomeric DNA G-quadruplex has been identified as a good therapeutic 
target in cancer treatment. G-quadruplex specific ligands that stabilize the G-quadruplex, 
have great potential to be developed as anticancer agents. Two crystal structures (an apo 
form of parallel stranded human telomeric G-quadruplex and its holo form in complex with 
BRACO19, a potent G-quadruple ligand) have been solved, yet the binding mechanism 
and pathway remains to be elusive. In this study, we simulated the binding of a free 
BRACO19 molecule to the apo form of the G-quadruplex using the latest AMBER DNA 
(OL15) and ligand GAFF2 force field. Three binding modes have been identified: top 
stacking, bottom intercalation and groove binding. Bottom intercalation (51% of the 
population) resembles the bottom binding pose in the complex crystal structure very well. 
The groove binding mode is less stable than the bottom binding mode, and is likely to be 
an intermediate state leading to bottom binding mode. A flip-insertion mechanism was 
observed in the bottom intercalation mode, during which the flipping out of the bases made 
space for ligand insertion, followed by bases flipping back to increase the stability of the 
complex. In addition to reproducing correct base-flipping behavior for some loop residues 
upon the ligand binding, the direct alignment type of ATAT-tetrad was observed in our 
simulations for the first time. These successes provide an initial support for using this force 




3.2 Introduction  
In a guanidine-rich sequence, the formation of eight Hoogsteen H-bonds between 
four guanine bases instead of the typical Watson–Crick H-bonds observed in duplex DNA, 
leads to a square-planar configuration known as G-tetrad. And multiple G-tetrads further 
stack together to form a G-quadruplex. G-quadruplex can be formed by one, two or more 
strands of DNA or RNA and can fold into diverse topologies.(Burge, Parkinson, Hazel, 
Todd, & Neidle, 2006) The electron dense void generated by the oxygens of the adjacent 
guanidine bases are typically filled by a monovalent cation stabilizing the whole G-
quadruplex structure. And as the K+ and Na+ are the pronounced cations, the G-
quadruplexes with these cations are physiologically favored. Accounting to the better co-
ordination of K+ with eight oxygens of four guanidine bases, it is preferred over Na+.(Burge 
et al., 2006; Collie, Sparapani, Parkinson, & Neidle, 2011) Computational tools have 
identified over 350,000 putative G-quadruplex sequences in the human genome, both the 
promoter regions of genes as well as within telomeres. (Huppert & Balasubramanian, 2005, 
2007) Evidence supporting G-quadruplex formation in human cells has been reported in 
various studies.(Biffi, Tannahill, McCafferty, & Balasubramanian, 2013; Di Antonio, 
Rodriguez, & Balasubramanian, 2012; Hänsel et al., 2009; Hänsel et al., 2011b; Hänsel, 
Löhr, Trantirek, & Dötsch, 2013) In particularly, G-quadruplexes are over-represented 
specifically in areas of DNA damage in cancer cells and happen to appear more frequently 
in tumors than in normal tissues.(Cree & Kennedy, 2014; Duchler, 2012; Onel, Lin, & 
Yang, 2014; Shalaby et al., 2013) For that reason, G-quadruplexes are becoming important 




Neidle, 2011; Cree & Kennedy, 2014; Duchler, 2012; Onel et al., 2014; Shalaby et al., 
2013) 
The first therapeutically important G-quadruplex formation was observed in the 3’-
end overhang of human telomeric DNA(Doluca, Withers, & Filichev, 2013b). The 
telomeric overhang with a length of 100-200 nucleotides, containing repeats of the 
sequence d(TTAGGG), is capped by Shelterin complexes.(Chung et al., 2013b; de Lange, 
2005b; Moyzis et al., 1988b; Wright, Tesmer, Huffman, Levene, & Shay, 1997a) After 
each cell replication, the telomere truncates by 50-200 base pairs and when the telomere is 
exhausted and Hayflick limit is reached, cell senescence and apoptosis are 
triggered(Harley, Futcher, & Greider, 1990b; Zakian, 1995b). In cancer cells, a reverse 
transcriptase called telomerase which is overexpressed in 80-85% of tumor cells, adds 
nucleotides to the telomere thus immortalizing the cells.(Greider & Blackburn, 1989a; 
Moorhouse et al., 2006b) It has been reported that the telomere cannot be hybridized by 
telomerase when the 3’ overhang folds into a G-quadruplex (Zahler, Williamson, Cech, & 
Prescott, 1991b), leading to the inhibition of telomerase and thus cell apoptosis. In addition, 
the telomeric G-quadruplex adopted by the guanidine-rich 3’ overhang prevents the 
binding of telomere protection proteins, which causes chromosomal fusions and stimulate 
cell apoptosis.(Denchi & de Lange, 2007b; Doluca et al., 2013b) Therefore, the G-
quadruplex ligands that stablize the G-quadruplex are considered as promising anti-cancer 
agents and are under intensive development.(Hänsel et al., 2011b) Tricyclic aromatic 
chromophore based G-quadruplex binding molecules has been identified. The activity of 
these molecules was optimized by substituting side chains with amido-alkylamino 




reporting better proportion between IC50 of 10-13 µM against various ovarian tumor cell 










BRACO19 (Figure 29), a computationally designed G-quadruplex ligand targeting 
the parallel-stranded G-quadruplex binding site(Yang & Okamoto, 2010b), inhibits 
telomerase, causes telomere shortening and also produces end-to-end chromosomal fusions 
in cancer cells. (Incles et al., 2004) It shows significant in-vivo anticancer activity in 
various tumor cell lines (Table 110)(Akagi & Kimoto, 1976; Alizadehnohi, Nabiuni, 
Nazari, Safaeinejad, & Irian, 2012; Brandes & Hermonat, 1983; Burger et al., 2005; Chen, 
Drabkowski, Hay, Macy, & Peterson Jr, 1987; Fang & Aust, 1997; Gunaratnam et al., 
2007; Harrison et al., 2004; Kellner, Wierda, Shpall, Keating, & McNiece, 2016a; Landers, 
Cassel, & George, 1997; Mickey et al., 1977; Morimoto, Safrit, & Bonavida, 1991b; 
Nichols et al., 1977; Olopade et al., 1992b; Rankin, Faller, & Spanjaard, 2008a; G. T. Zhou 




Table 110  
In vivo activity of BRACO19 against various cancer cell lines. 
Cell lines Tissue type IC50 
MCF7 Breast cancer (human) 
(Brandes & Hermonat, 1983) 
2.5 μM 
(Gunaratnam et al., 2007) 
A549 Lung cancer (human) 
(Fang & Aust, 1997) 
2.4 μM 
DU145 Prostate cancer (human) 
(Mickey et al., 1977) 
2.3 μM 
HT-29 Colon cancer (human) 
(Chen et al., 1987) 
2.7 μM 
HGC-27 Gastric carcinoma 
(Akagi & Kimoto, 1976) 
2.6 μM  
A2780 Ovarian cancer (human) 
(Alizadehnohi et al., 2012) 
2.5 μM 
WI-38 Lung fibroblast (human) 
(Landers et al., 1997) 
10.7 μM 
(Gunaratnam et al., 2007) 
IMR90 Lung fibroblast (human) 
(Nichols et al., 1977) 
>25 μM 
U87 Glioblastoma (human)  
(Olopade et al., 1992a) 
1.45 μM 
(G. T. Zhou et al., 2016) 
U251 Glioblastoma (human) 1.55 μM 
SHG-44 Glioma (human) 2.5 μM 
UXF1138L Uterus carcinoma (human) 2.5μM 
(Burger et al., 2005) 
CH1 Lymphoma (mouse) 10.1μM 
(Harrison et al., 2004) 
SKOV3 Ovarian cancer (human)  
(Morimoto, Safrit, & Bonavida, 1991a) 
13.0μM 
CLL Chronic lymphocytic leukemia 
(Kellner, Wierda, Shpall, Keating, & 
McNiece, 2016b) 
80μM 
(Rankin, Faller, & 
Spanjaard, 2008b) 
AML Acute myeloid leukemia 80μM 
(Rankin et al., 2008a) 
-- Prolymphocytic leukemia 80μM 




In addition, BRACO19 also demonstrates broad anti-viral activity by stabilizing the 




parallel telomeric G-quadruplex d(TAGGGTTAGGGT)2 with and without BRACO19 









Figure 30. Comparison between apo and holo crystal structure of a parallel telomeric DNA 
G-quadruplex. (A) The holo structure of the telomeric DNA G-quadruplex in complex with 
BRACO19 (PDB: 3CE5).  (B) Superimposition of the apo and holo form. (C) Cartoon 
representation of the holo form highlighting the four layers formed by DNA bases. (D) The 
holo structure of the telomeric DNA G-quadruplex in complex with BRACO19 at the 
bottom (PDB: 3CE5). (E) Cartoon representation of the apo form highlighting the five 





In the holo form, BRACO19 molecule binds at the interface of two parallel folded 
G-quadruplexes, sandwiched between a G-tetrad and a AT tetrad (Figure 31), where ATA 






















The comparison of the holo form with the apo form indicates that the binding of 
BRACO19 induces some local conformational changes in the G-quadruplex. First, the 
bases of T6, T7 and A8 flip out in the holo form with respect to the apo form, probably 
facilitating the insertion of the 3-pyrrolodino-propionamido branch of BRACO19. Second, 
the two adenine bases (residues 2 and 14) and the two thymine bases (residues 1 and 13) 
are paired in the apo form whereas in the holo form, the residues 1, 2 and 14 in are paired 
leaving the thymine residue, 13, unpaired. These local conformational adjustments clearly 
indicate that the intercalation of BRACO19 into the G-quadruplex follows an induced-fit 
binding mechanism rather than lock-key. Yet, the binding pathway and detailed mechanism 
remain elusive. The induced fit binding mechanism proposes that the initial weak binding 
interactions between ligand and receptor induce conformation changes in the receptor and 
ligand; and these changes in turn facilitate better binding affinity and specificity. Therefore 




essential in designing more potent drugs. Furthermore, this intercalation mode with these 
subtle local conformational changes from the experimental structure also provides an 
excellent test to check whether molecular dynamics (MD) simulation based on the latest 
force fields is accurate enough to reproduce this binding mode.  
MD stability simulations with various force fields have been widely used in 
studying G-quadruplexes in complex with BRACO19 and other ligands. Moore et al 
modelled 22mer parallel G-quadruplex with BRACO19 analogs; and conducted MD 
simulations to probe the qualitative structure-activity relationships (Moore et al., 2006a) 
using the AMBER parm99 force field.(Cornell et al., 1996; Jorgensen, Chandrasekhar, 
Madura, Impey, & Klein, 1983b; J. M. Wang, Cieplak, & Kollman, 2000; J. M. Wang, R. 
M. Wolf, J. W. Caldwell, P. A. Kollman, & D. A. Case, 2004) Hou et al conducted stability 
simulations using the AMBER parm99 force field(Duan et al., 2003; J. M. Wang et al., 
2004) on G-quadruplex in complex with BRACO19 and 5 other ligands; and revealed that 
the H-bonds in the G-quadruplex to be major contributors for the stability of the G-
quadruplex and ligand-quadruplex complex.(J. Q. Hou et al., 2010a) Dhamodharan et al 
docked bis-quinolinium and bis-pyridinium derivatives of 1,8-naphthyridine to an 
antiparallel G-quadruplex and consequently, conducted MD simulations; and reported that 
end-stacking was the favored binding mode.(Dhamodharan, Harikrishna, Jagadeeswaran, 
Halder, & Pradeepkumar, 2012b) Jain et al docked dimeric 1,3-phenylene-bis(piperazinyl 
benzimidazole)s to a 22mer parallel G-quadruplex, ran MD simulations and reported that 
both end-stacking and groove-binding were favored.(Jain, Paul, Maji, Muniyappa, & 
Bhattacharya, 2012a) Using docking and MD simulations based on AMBER 




2014; Di Leva, Novellino, Cavalli, Parrinello, & Limongelli, 2014) force field, Ungvarsky 
et al successfully characterized the binding pose of a set of novel BRACO19 derivatives to 
the human telomeric parallel G-quadruplex.(Ungvarsky et al., 2014a) Zhou et al employed 
steered molecular dynamics and umbrella simulations using the charmm27 force 
field(MacKerell et al., 1998) to understand the ligand unbinding from human telomeric 
antiparallel G-quadruplex.(J. K. Zhou, Yang, & Sheu, 2015a) Recently, Diveshkumar et al 
identified indolyl, methylene-indanone scaffolds, by docking and conducting MD 
simulations using AMBER DNA parm99 force field with the updates of parmbsc0 and 
χOL4 refinement(Cheatham, Cieplak, & Kollman, 1999; Krepl et al., 2012a) on various G-
quadruplexes (PDB IDs: 2L7V, 2O3M, 1KF1, 143D, and 2MB3), which specifically binds 
to parallel promoter G-quadruplexes rather than telomeric DNA G-quadruplex or duplex 
DNA(Diveshkumar et al., 2016a). However, these stability simulations don’t provide 
detailed information on the binding pathway.  
A recent AMBER DNA force field OL15 has been developed to include the 
corrections on several backbone torsional angle parameters (i.e. βOL1(Zgarbová et al., 
2015), εζOL1(Zgarbová et al., 2013)and χOL4(Krepl et al., 2012a) to ff99bsc0(Galindo-
Murillo et al., 2016)). These corrections are expected to improve the backbone sub-state 
description in G-quadruplexes and Z-DNA. So far, the tests on a DNA force field is mainly 
limited to long stability simulations on various DNA systems including B-DNA, Z-DNA, 
duplexes, triplexes, G-quadruplexes as well as unfolding simulations of DNA 
duplex.(Galindo-Murillo et al., 2016; Ivani et al., 2016; Sponer, Cang, & Cheatham, 2012; 
Zgarbová et al., 2013; Zgarbová et al., 2015) The performance of this DNA force field 




field on the binding simulations of ligand to G-quadruplexes is yet to be validated. During 
which the local unfolding and refolding of the bases particularly, base flipping is expected 
and thus provide a good test for the backbone torsional angle parameters of the improved 
DNA force field OL15. In this study, MD free binding simulations of unbound ligand-
DNA complex were utilized to probe the binding pathway and mechanism of BRACO19 
to the human telomeric parallel G-quadruplex DNA and stability simulations of two crystal 
binding poses were used to generate reference structures under physiological solution 
conditions and to understand the limitations of X-ray crystal packing. While the crystal 
bottom pose was stable, the crystal top pose altered significantly. In our free binding 
simulations, the three major binding modes were observed: top stacking, bottom 
intercalation and groove binding modes. The most abundant mode, the bottom intercalation 
mode, resembles the MD relaxed crystal pose well. Encouragingly, the local conformation 
adjustments were observed in the simulated structures. For the bottom intercalation mode, 
these conformational changes are consistent with the crystal pose in terms of the backbone 
torsion angles. These provide an initial evidence to the correctness of the torsion parameter 
corrections made to the OL15 force field. The dynamic and energetic properties of the three 
major binding modes were thoroughly studied, providing vivid examples of induced-fit 









Table 111  


















N/A 1 1491 3 Cl- 41.5 1 N/A 1 499 
G-Quad(1K8P)2 0 5141/4639 20/22 62.5/60.9 2x1 N/A 1 499 
G-Quad(3CE5) 1 5114 17 62.5 1 top pose 1 999 
G-Quad(3CE5) 1 5075 19 62.5 1 bottom pose 1 999 










A B C 
Figure 32. The initial configuration of the simulation system (DNA Quadruplex + 
Unbound BRACO19). 5’ and 3’ of the telomeric G-quadruplex DNA are indicated by a red 
and blue ball, respectively.  Residues 1, 2, 13, 14 are indicated in purple and residues 12, 
24 are indicated in red and the K+ ions are represented in yellow. 
 
 
                                                             
1 Triclinic box equivalent to the true truncated octahedral box 




A DNA-ligand system was constructed, using the X-ray solved human telomeric 
DNA G-quadruplex (Figure 32C, PDB ID: 1K8P(Parkinson, Lee, & Neidle, 2002)) with 
an unbound BRACO19 10 Å away from the G-quadruplex, to simulate 10 simulation runs. 
This 10 Å distance was to ensure that there were at least three layers of water molecules 
separating ligand and DNA, and thus enabling the simulations to start from an unbound 
state to probe the binding pathways and mechanisms. The four non-standard brominated 
Uracil residues were replaced by standard Thymine residues in the original PDB structure. 
Two bound DNA-ligand systems, one characterizing bottom intercalation mode (Figure 
32A, BRACO19 stacked below the G-tetrad formed by residues G5, G11, G17 and G23) 
and other characterizing top stacking mode (Figure 32B, BRACO19 stacked above the 
ATA formed by residues A2, T13 and A14) were constructed from the bound X-ray solved 
human telomeric DNA G-quadruplex (PDB ID: 3CE5) and simulated. Note that the crystal 
structure characterizing top stacking mode is missing two terminal residues, G23 and T24, 
in the second chain. A water box of a truncated octahedron, 10 Å water buffer and K+ to 
act as counter ions, was used to solvate the unbound and bound systems. For the unbound 
system, the water buffer starts from the outmost atom of the ligand to the box surface. A 
TIP3P model (Jorgensen, Chandrasekhar, Madura, Impey, & Klein, 1983a) represented the 
water molecules, a K+ model recently developed by Cheatham group and a refined version 
of the AMBER OL15 with the addition of corrections βOL1, εζOL1 and χOL4 to ff99bsc0 
(Galindo-Murillo et al., 2016) represented the DNA G-quadruplex(Joung & Cheatham, 
2008a). The standard AMBER protocol was used to generate the partial charges of 
BRACO19 with 3+ charge at physiological pH=7; HF/6-31G* level was used to obtain the 




Static Potential) method was then used to generate the partial charges(Bayly, Cieplak, 
Cornell, & Kollman, 1993b) and AMBER GAFF2(J. M. Wang et al., 2004) force field 
provided the other parameters.   
3.3.2 Simulation protocols. The AMBER 16 package(Case et al., 2016) was used 
to conduct 12 simulation runs for the unbound DNA-ligand system, 1 simulation run for 
BRACO19 only and 1 simulation for G-Quadruplex only (Table 111).  After the potential 
energy of the system was minimized, 14 independent simulation runs were conducted with 
different initial velocities, which were assigned based on random seeds. For the free 
binding system, an extra 500 ps pre-run at high temperature (500 K) was carried out to 
randomize the position and orientation of the free ligand(Lei, Wang, & Wu, 2012a), while 
the receptor was fixed. A short 1.0 ns molecular dynamics in the NPT ensemble mode 
(constant pressure and temperature) was used to relax the system density with cartesian 
restraints (1.0 kcal/mol/Å) on the ligand and the G-quadruplex and then 499.0 ns dynamics 
for unbound systems and 999.0 ns dynamics for bound systems in the equivalent NVT 
ensemble mode (constant volume and temperature) was run at 300 K. 2.0 fs time step was 
enabled in the simulations by applying SHAKE(Ryckaert, Ciccotti, & Berendsen, 1977a) 
to constrain all bonds connecting hydrogen atoms. The long-range electrostatic interactions 
were treated with the particle-mesh Ewald method(Essmann et al., 1995a) under periodic 
boundary conditions (charge grid spacing of ~1.0 Å, the fourth order of the B-spline charge 
interpolation; and direct sum tolerance of 10–5 ). For the short-range non-bonded 
interactions, the cutoff distance was 10 Å; and the long-range van der Waals interactions 
were based on a uniform density approximation. A two-stage RESPA approach(Procacci 




updating short range forces was once per time step and long range forces was twice per 
time step . The Langevin thermostat with a coupling constant of 2.0 ps was used to control 
the temperature. The trajectories were saved at 100.0 ps intervals for analysis. 
3.3.3 Convergence of simulations. The root mean square deviation (RMSD) of 
DNA backbone and ligand-DNA atom contacts using a cutoff of 3.0 Å were used to 
monitor the convergence of the simulations. Attaining a steady bound state and the stability 
of the bound state was indicated by the flat and small RMSD of 2.5 Å (Figure 60) and the 
stable contact number (Figure 61) in the last 200 ns. A complex with the number of atom 
contacts greater than 40 is defined as a stable complex. A good sampling of the binding 
sites is indicated by the free drugs are binding to different sites as shown in the last 
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Figure 33. Last snapshots of the ten quadruplex-BRACO19 simulations. 5’ and 3’ of the 
telomeric G-quadruplex DNA are indicated by a red and blue ball, respectively.  Residues 
1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red and the K+ ions 
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3.3.4 Binding mode identification. DNA backbone of the stable complexes from 
the trajectories were aligned by least square fitting as the DNA backbone remained 
relatively stable. Daura algorithm(Daura et al., 1999a) was used to cluster the aligned 
complexes into different structural families based on the ligand’s 2 Å pair-wise RMSD 
cutoff without fit. Every structural family is represented by the centroid structure. The 
centroid structure of the populated structural families (>1% of total structure population) 
are shown in Table 112. Based on visual inspection, these centroid structures were further 
merged into three major binding modes: top stacking, bottom stacking and groove binding 




Table 112  
Representative structures of the most populated complex structure families (population ≥ 
1 %) from the clustering analysis of the combined binding trajectories. 5’ and 3’ of the 
telomeric G-quadruplex DNA are indicated by a red and blue ball, respectively. Residues 
1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red. 
Binding model Top Stacking 


















Table 112 (continued) 
Binding model End Intercalation (Bottom) 













   







Table 112 (continued) 
Binding model Groove Binding 


















3.3.5 Parameters for characterizing DNA-drug binding pathway. The DNA-
drug binding process was characterized by five order parameters: MM-PBSA binding 
energy (ΔE), center-to-center distance (Å), K+-K+ distance, ligand RMSD, drug-base 
dihedral angle, and hydrogen bond analysis. In order to avoid large energy fluctuation of 
explicit solvent, the energetics of the bound complexes were analyzed using MM-
PBSA(Tan, Tan, & Luo, 2007) (Molecular Mechanics Poisson-Boltzmann/Surface Area) 
module in the AMBER package (PB1 model with mBondi radii set, salt concentration of 




MM-GBSA(Gregory D. Hawkins, Christopher J. Cramer, & Donald G. Truhlar, 1995; 
Hawkins, Cramer, & Truhlar, 1996; Tsui & Case, 2000) (Molecular Mechanics 
Generalized-Born/Surface Area) module in AMBER package (GB1 model with mBondi 
radii set, at various ionic strengths of 0.0 M, 0.05 M, 0.1 M, 0.15 M and 0.2 M, and surface 
tension of 0.00720 kcal/mol/Å2) was also used to characterize the binding affinities of 
different binding modes. An evaluation study by Case et al. suggested that the GB1 model 
performs better than GB2-OBC1 and GB5-OBC2.(Gaillard & Case, 2011) To include the 
conformation energy change, the MM-PBSA/MM-GBSA binding energy for a system was 
calculated from three simulations(Kelly Mulholland, Siddiquei, & Wu, 2017): ligand only, 
DNA only and DNA-ligand complex. The center-center distance was defined as the 
distance between the center of the DNA G-quadruplex and BRACO19. The K+-K+ distance 
is defined as the distance between the K+ ions in the G-quadruplex DNA. Receptor and 
ligand RMSD for bottom and groove binding mode were calculated with reference to the 
last snapshot of the simulation of bound crystal complex characterizing bottom 
intercalation mode (PDB ID: 3CE5); and receptor and ligand RMSD for top stacking was 
with reference to the last snapshot of the simulation of bound crystal complex (PDB ID: 
3CE5) characterizing top stacking mode. The dihedral angle was defined as the angle 
between the plane of the top layer of the G-tetrads of the DNA G-quadruplex and the 
BRACO19’s center, the plane of the acridine ring. The geometric definition of H-bonds: 
distance cutoff between the donor and acceptor was 3.5 Å and the angle cutoff between the 
same with -H was 120°. The H-bonds were defined and calculated for the five base layers 
over the course of the trajectories: the first/AT-tetrad (T1, A2, T13 and A14), the 




tetrads (G4, G10, G16 and G22) the fourth/bottom layer of the G-tetrads and the fifth/T-
dyad (T12 and T24) illustrated in (Figure 71). The standard backbone dihedral angles (α, 
β, γ, δ, ε and ζ) around the covalent bonds of the deoxyribose and χ about the glycosidic 
bond were defined to characterize the conformational changes. The defined dihedral angles 











Two bound DNA-ligand systems, one characterizing bottom intercalation mode 
and other characterizing top stacking mode, were simulated to characterize the stability of 
the binding modes observed in the X-ray solved human telomeric DNA G-quadruplex 
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Figure 35. Stability simulation of the bottom binding mode in the crystal structure (PDB: 
3CE5). Top: Representative structures with time annotation. 5’ and 3’ are indicated by a 
red and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 
12, 24 are indicated in red and the K+ ions are represented in yellow. Bottom: An order 
parameter plot depicting number of hydrogen bonds present in first (red), second G4 
(cyan), third G4 (blue), fourth G4 (black) and fifth (green) layers of the DNA structure 
(Figure 71), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative 
to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) 




3.4.1 The crystal bottom intercalation mode of BRACO19 was stable. The 
simulation of DNA-ligand system characterizing bottom intercalation mode illustrated a 
stable binding mode (Figure 35) as indicated by the small receptor and ligand RMSD and 
drug-base dihedral angle in the order parameter plot. The planarity observed in the crystal 
structure (Figure 37A) is lost and conformational changes are observed in 3-pyrrolodino-
propionamido branches of BRACO19. This loss of planarity is explained by the absence 
of stacking between two tetrads, G-tetrad and an ATAT-tetrad, as observed in the crystal 
structure (Figure 31). The ligand interactions of BRACO19 with the G-quadruplex in 
crystal structure (bottom pose) and MD relaxed crystal structure (bottom pose) are 
compared (Figure 70).  
And the final MD relaxed crystal structure illustrated (i) the acridine ring stacked 
on residue, G5 (ii) the protonated N in the acridine ring formed a H-bond with T12, (iii) 
the 3-pyrrolodino-propionamido side chain at the 6th position formed a H-bond with G17 
and (iv) the other 3-pyrrolodino-propionamido side chain at the 3rd position formed a H-
bond with G11 (Figure 70 (B)) whereas in the crystal structure the acridine is stacked on 
residues G5 and G23 and the N from the amide of the 3-pyrrolodino-propionamido side 
chain on 3rd position formed a H-bond with T12 (Figure 70 (A)). Formation of TT-dyad 
and ATAT-tetrad are also observed (Figure 71) and illustrated in the order parameter plot 
by increase in the number of H-bonds (Figure 35). This explains that its formation was 
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Figure 36. Stability simulation of the top binding mode in the crystal structure (PDB: 
3CE5). Top: Representative structures with time annotation. 5’ and 3’ are indicated by a 
red and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 
12, 24 are indicated in red and the K+ ions are represented in yellow. Bottom: An order 
parameter plot depicting number of hydrogen bonds present in first (red), second G4 
(cyan), third G4 (blue), fourth G4 (black) and fifth (green) layers of the DNA structure 
(Figure 71), the drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative 
to the original crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) 




3.4.2 The crystal top mode of BRACO19 changed significantly, caused by lack 
of crystal packing constraints. The simulation of DNA-ligand system characterizing top 
stacking mode illustrated an unstable binding mode. The ligand moves away from the G-
quadruplex and binds again although not in the same orientation as illustrated in Figure 36. 
This is demonstrated by the ligand RMSD and drug-base dihedral angle. Concluding that 
the top stacking mode is due to crystal packing constraints. The ligand interactions of 
BRACO19 with the G-quadruplex in crystal structure (top pose) and MD simulated crystal 
structure (top pose) are compared (Figure 70). And the final MD simulated crystal structure 
illustrated (i) acridine ring stacked on residue A14, in the 3-pyrrolodino-propionamido side 
chain at the 6th position, (ii) the pyrrolodino ring formed a H-bond with A2 and (iii) the O 
from the amide formed H-bond with A14 and in other 3-pyrrolodino-propionamido side 
chain at the 3rd position, (iv) the pyrrolodino ring formed a H-bond with A14 and (v) the 
protonated N in the acridine ring was also interacting with A14 (Figure 70 (E)) whereas in 
the crystal structure the acridine is stacked on A14 and the side chain at the 6th position 
formed a salt bridge with G21 (Figure 70 (D)). The K+ ion moves out of the G-quadruplex 





































































































Figure 37. The MD relaxed crystal structure of (A) bottom intercalation mode and (B) top 
stacking mode (PDB ID: 3CE5) and the major binding modes, (C) bottom intercalation 
mode (D) top binding mode and (E) groove binding mode from the binding simulations. 
BRACO19 is shown in licorice; 5’ and 3’ of the telomeric G-quadruplex DNA are indicated 
by a red and blue ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and 





















3.4.3 Three drug binding modes were observed in free binding DNA-ligand 
simulations. 10 simulation runs (500 ns of each) were executed to study the binding 
pathway of BRACO19 to the telomeric DNA G-quadruplex. The convergence of the 
binding simulations was confirmed (see the method section). Starting at an unbounded 
state, the ligand was observed to bind to the top and bottom of the G-quadruplex in seven 
runs (run 2, 3, 4, 5, 6, 7 and 9, Figure 33) and to the groove/side of the G-quadruplex in the 
remaining three runs (run 1, 8 and 10, Figure 33) at 500 ns. Six structural families with 
over 1% population were obtained from the clustering analysis (Table 112). Three binding 
modes were identified from these six structural families (Figure 37): top stacking (11.9 % 
of the total population), bottom intercalation (51.1%) and groove binding (9.6%). 
Encouragingly, the bottom pose is very similar to the ligand pose in the crystal complex 
structure (Figure 37A, 37C). In the bottom-intercalation mode, BRACO19 is sandwiched 
between the bottom G-tetrad and T-dyad. This pose is very consistent with the bottom 
intercalation pose of BRACO19 in the crystal structure (Figure 37A, 37C): a) the similar 
position and orientation of BRACO19; b), the intercalation between G-tetrad and T-dyad; 
c) flipping out of the bases A8 and T7. Subtle differences were also observed: a). a higher 
planarity of BRACO19 in the crystal structure; b) flipping out of T6 in the crystal structure; 
c). pairing between T12 and T24 in the MD structure.  
The high planarity of BRACO19 in the crystal structure might be accounted by the 
fact that it is stacked between an ATAT-tetrad and a G-tetrad; and the paring between T12 
and T24 is blocked by the formation ATAT-tetrad in the crystal structure (Figure 31). This 
ATAT-tetrad comprises a thymine residue from the top G-quadruplex and two adenine 




between the MD simulated structure and the crystal structure for this pose is ~1 Å, 
indicating the high accuracy of the MD prediction. In the top binding pose, BRACO19 
stacks on the top of the ATAT-tetrad, which is formed on the top of the first G-tetrad 
(Figure 37D). In addition, the pairing between T12 and T24 and the flipping in of the bases 
T6, T7 and A8 are observed in the top binding pose. In the groove binding mode, 
interaction of BRACO19 with the groove, pairing between T12 and T24 and flipping out 
of the bases T6, T7 and A8 are observed (Figure 37E). The groove binding pose appears 
to be the intermediate binding pose of the end binding mode based on our binding pathway 
(will be further discussed later). To characterize the conformational changes in the DNA 
backbone upon binding, the dihedral angles were calculated for each residue in every 
binding mode and compared with the simulated crystal poses. For the stability simulations 
of the X-ray poses and the free binding simulations, the residues in three G-tetrads show 
minimum fluctuations whereas the residues in terminal layers, ATAT-tetrad and T-dyad 
larger fluctuations were observed. Encouragingly, the dihedral angles of the residues in the 
representative structures of free binding simulations are consistent with most of the 
residues in the crystal structures of stability simulations. This data supports the torsional 
parameter corrections (βOL1, εζOL1 and χOL4) to the OL15 DNA force field. 
3.4.4 The stable G-Quadruplex backbone scaffold is maintained as indicated 
by the flat and small RMSD of ~2.5 Å in all trajectories (Figure 60). For the five base 
layers in the G-quadruplex (Figure 71), while the middle three G4 are the stable ones 
(maintained in all the representative structures), the first and fifth layers are less stable and 
modulated by ligand binding. Among the three G-tetrad layers, the most stable G-tetrad is 




H-bonds and the bottom G-tetrad with ~5 H-bonds in all trajectories. The detailed account 
of H-bonds maintained in the representative structure of different binding poses with 
respect to the experimentally solved X-ray crystal structure is illustrated in Figure 71.  
The binding pathway of the three binding modes was characterized by calculating 
the five order parameters as described in the methods section. A representative trajectory 
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Figure 38. A representative trajectory of the bottom intercalation mode. Top: 
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue 
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are 
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter 
plot depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4 
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure (Figure 71), the 
drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative to the crystal 
pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and MM-PBSA 




3.4.5 Bottom intercalation of BRACO19 follows the flip-insertion mechanism. 
In the representative trajectory of the bottom intercalation mode (Figure 38), the first 
interaction between the G-quadruplex and BRACO19 occurred at about 2 ns from the 
starting unbound state. Interestingly, successful intercalation of BRACO19 was observed 
at 248 ns as the bases of T12 and T24 paired over BRACO19 and the bases, A8 and T7 
flipped out. It was noted that the initial contact with the G-quadruplex is concurrent with 
flipping out of the residues, T12 and T24 making space for BRACO19 to interact with G-
tetrad. Once BRACO19 stacked below the bottom G-tetrad, the bases of T12 and T24 
flipped back and paired to form two hydrogen bonds (Figure 71). As a result, the ligand is 
sandwiched between the bottom G-tetrad and the T-dyad of the G-quadruplex, leading to 
a stable intercalation mode with stable order parameters (ligand RMSD of ~1 Å and MM-
PBSA binding energy of ~-30 kcal/mol). Clearly, the drug binding facilitates the formation 
of T-dyad (Figure 38). We name this intercalation as “flip-insertion” mechanism. This 
mechanism is also observed in the other representative trajectory of bottom intercalation 
mode. The ligand interactions of BRACO19 with the G-quadruplex in MD relaxed crystal 
structure (bottom pose) and the representative structure of bottom intercalating trajectory 
from the free binding simulation are compared (Figure 70). And the final MD simulated 
crystal structure illustrated (i) the acridine ring stacked on residue G5, (ii) the protonated 
N in the acridine ring formed a H-bond with T12, (iii) the 3-pyrrolodino-propionamido 
side chain at the 6th position formed a H-bond with G17 and (iv) the other 3-pyrrolodino-
propionamido side chain at the 3rd position formed a H-bond with G11 (Figure 70 (B)) 
whereas in the representative structure of bottom intercalating trajectory from the free 




bond with T18, (iii) other formed H-bond with T12 and G11 and (iv) the side chain on 9th 












































































































































Another notable feature in this trajectory is the flipping out of the bases A8 and T7 
after the intercalation of BRACO19. This flipping out of the bases is also observed in the 
experimental X-ray solved crystal structure of G-quadruplex in complex with BRACO19, 
PDB ID: 3CE5 (Figure 30). These conformational changes are characterized by calculating 
the backbone dihedral angles of each base and comparing with its corresponding base in 
the stability simulation of the crystal bottom mode. Figure 39 features the dihedral angles 
of residue T7 in both representative trajectories of free binding and stability simulations 
characterizing the bottom intercalation mode. Starting at the different values, the torsional 
angles ε and ζ of residues from MD simulated crystal structure and free binding simulations 
converged. The changes in the torsional angles are concurrent with the flipping out of 
residue T7 from 323 ns through the rest of the trajectory with fluctuations. Therefore, 
correct torsional parameters appear to be critical for reproducing base flipping shown in 
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Figure 40. A representative trajectory of the top stacking mode. Top: Representative 
structures with time annotation. 5’ and 3’ are indicated by a red and blue ball, respectively. 
Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red and 
the K+ ions are represented in yellow. Bottom: A representative trajectory of the top 
stacking mode. An order parameter plot depicting number of hydrogen bonds present in 
first (red), second G4 (cyan), third G4 (blue), fourth G4 (black) and fifth (green) layers of 
the DNA structure (Figure 71), the drug-base dihedral angle, receptor (red) and ligand 
(black) RMSD relative to the crystal pose, center-to-center distance (R/black) and K+-K+ 















3.4.6 Top stacking of BRACO19 leads to the formation of ATAT-tetrad in a 
trajectory. The representative trajectory for the top stacking mode is shown in Figure 40 
with the 500-ns order parameter plot. In this trajectory, the first interaction of BRACO19 
with the top of the G-quadruplex occurred at about 18 ns from the starting unbound state. 
From about 18-42 ns of the trajectory, BRACO19 flipped orientation and the residues T1, 
A2, T13, A14 formed an ATAT-tetrad and remained stable through the rest of the 
simulation (ligand RMSD of ~3.5 Å and MM-PBSA binding energy of ~-25 kcal/mol). 
The formation of ATAT-tetrad(Zhang et al., 2001) by residues T1, A2, T13, A14 in the 
first layer is indicated by the fact that the number of H-bonds increases to ~6 from initial 
~3 in the first layer at 42 ns.  
The ligand interactions of BRACO19 with the G-quadruplex in MD simulated 
crystal structure (top pose) and the representative structure of top stacking trajectory of free 
binding simulation are compared (Figure 70). And the final MD simulated crystal structure 
illustrated (i) acridine ring stacked on residue A14, in the 3-pyrrolodino-propionamido side 
chain at the 6th position, (ii) the pyrrolodino ring formed a H-bond with A2 and (iii) the O 
from the amide formed H-bond with A14 and in other 3-pyrrolodino-propionamido side 
chain at the 3rd position, (iv) the pyrrolodino ring formed a H-bond with A14 and (v) the 
protonated N in the acridine ring was also interacting with A14 (Figure 70 (E)) whereas in 
the representative structure of top stacking trajectory of free binding simulation the N in 
the acridine formed a H-bond with T13 and (ii) N from the amide of side chain on 6th 






































































































































Occasional flipping out of the bases in the loops is also observed in this trajectory. 
Figure 41 features the dihedral angles of residue T7 in both stability simulation of the 
crystal top mode and the representative trajectory of the free binding simulations 
charactering top stacking mode. In the stability simulation trajectory, the residue T7 is 
flipped out from 74 ns to 95 ns, from 110 to 129 ns and from 258 to 333 ns with fluctuations 
mainly characterized by α and γ. In the free binding simulation trajectory, the residue T7 
is flipped out from 322 ns to 345 ns and from 395 ns to 462 ns and is mainly characterized 
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Figure 42. A representative trajectory of the groove binding mode. Top: Representative 
structures with time annotation. 5’ and 3’ are indicated by a red and blue ball, respectively. 
Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are indicated in red and 
the K+ ions are represented in yellow. Bottom: An order parameter plot depicting number 
of hydrogen bonds present in first (red), second G4 (cyan), third G4 (blue), fourth G4 
(black) and fifth (green) layers of the DNA structure (Figure 71), the drug-base dihedral 
angle, receptor (red) and ligand (black) RMSD relative to the crystal pose, center-to-center 
distance (R/black) and K+-K+ distance (R/red) and MM-PBSA binding energy (ΔE) (cf. 




3.4.7 Groove binding of BRACO19 might be an intermediate state for the end 
binding pose. In the representative trajectory of the groove binding mode, BRACO19 
made initial contact with the telomeric G-quadruplex at 34 ns (Figure 42). At 20 ns, two 
additional hydrogen bonds formed in the first base layer, indicating the formation of 
ATAT-tetrad. At ~271 ns, the ligand moved to the groove, but rather than remaining stable, 
it kept adjusting pose toward the G-quadruplex bottom end. This also was reflected in the 
large fluctuation of the five order parameters during 200-450 ns. This system reached a 
steady state at 450 ns, showing minor fluctuations through the rest of the trajectory. The 
terminal MM-PBSA binding energy is ~20 kcal/mol, which is much lower than that of the 
top stacking (-25 kcal/mol) and the bottom binding mode (~30 kcal/mol). Therefore, this 
system can further be converted into an end binding pose. In fact, the conversion from a 
groove binding pose to a bottom binding pose was observed at 236 ns in this trajectory 
indicated by ligand RMSD and drug-base dihedral angle in the order parameter plot and 
the conversion to a top binding pose was observed in another representative groove binding 
trajectory. BRACO19 initially bound to the side of the telomeric G-quadruplex at 9 ns, 
slightly moved down and bound to a groove at 86 ns, but moved out and bound to the top 
at 345 ns, and then remained in this binding mode through the rest of the trajectory. The 
van der Waals energy difference between groove binding pose and end binding pose might 
be the driving force. The ligand interactions of BRACO19 with the G-quadruplex in the 
representative structure of the groove binding trajectory and the representative structure of 



























































































































































In the representative structure of the bottom intercalating trajectory (i) the acridine 
is stacked on G23, (ii) one pyrrolidine ring formed H-bond with T18, (iii) other formed H-
bond with T12 and G11 and (iv) the side chain on 9th position is stacked on G5 (Figure 70 
(C)) whereas in the representative structure of the groove binding trajectory the acridine is 
stacked on G17, (ii) pyrrolidine ring of side chain on 3rd position formed a H-bond with 
G17, (iii) N from the amide of side chain on 6th position formed a H-bond with G23 and 
(iv) the secondary amine from the side chain on 9th position formed a H-bond with T12 
(Figure 70 (G)). 
Occasional flipping out of the bases in the loops is also observed in this trajectory. 
Figure 43 features the dihedral angles of residue T18 in representative trajectories of 
stability simulations charactering crystal bottom intercalation mode and free binding 
simulations charactering groove binding mode. In the stability simulation, the residue T18 
does not flip out at all and this is characterized by the minimum fluctuation of ε and ζ. In 
the free binding trajectory, the residue T18 is flipped out at 276 ns remains as such through 




Table 113  
MM-PBSA energy of BRACO19 to the G-Quadruplex DNA in different binding modes. 
Binding Pose 3ΔVDW 4ΔSUR 5ΔPB-ELE 6ΔCONF 7ΔTOT 8ΔΔE 
Top Stacking -60.1±6.2 29.4±3.3 11.2±5.5 -5.6±6.7 -25.1±6.7 4.2 
Groove Binding -42.7±5.3 22.2±3.0 6.5±6.1 -14.9±4.8 -26.1±6.6 3.2 
Bottom Intercalation -84.8±4.2 36.6±1.8 18.0±5.0 0.9±2.7 -29.3±5.7 0 
                                                             
3 VDW = Change of VDW energy in gas phase upon complex formation (Units: kcal/mol) 
4 SUR = Change of energy due to surface area change upon complex formation (Units: kcal/mol) 
5 PB-ELE = Change of PB reaction field energy + Elec. energy upon complex formation (Units: kcal/mol) 
6 CONF = Change of energy due to conformational changes (Units: kcal/mol) 
7 TOT = (ΔVDW +ΔSUR + ΔPB-ELE + ΔCONF) Change of potential energy upon complex formation  




3.4.8 MM-PBSA binding energy data ranks the bottom intercalation mode as 
the most stable mode among the three binding modes. The relative stability of the three 
binding modes was examined by conducting MM-PBSA binding energy calculations on 
each mode. The best binding energy toward the G-quadruplex (-29.3±5.7 kcal/mol) is 
observed in the bottom intercalation, making this the most favorable binding pose. The -
25.1±6.7 kcal/mol and -26.1±6.6 kcal/mol binding energies of top stacking and groove 
binding respectively are quite comparable. To further understand the nature of binding, the 
binding energy was fragmented into van der Waals (VDW) interaction, hydrophobic 
interaction (SUR), and electrostatic interaction (PB-ELE) (Table 113). As demonstrated in 
the Table 113, most of the binding interactions are contributed by van der Waals 
interactions. As expected, the most favorable VDW energy was demonstrated by the 
bottom stacking pose (-84.8±4.2 kcal/mol), which is 24.7 kcal/mol more favorable than 
that of top stacking pose and 42.1 kcal/mol more favorable than that of the groove binding 
pose. This high VDW interactions of the bottom intercalation mode can be accounted by 
the interaction of BRACO19 with a G-tetrad and a T-dyad whereas, the top stacking mode 
and groove binding modes are only interacting with an ATAT-tetrad and the residues in 
the loop, respectively. MM-GBSA binding energies were also calculated for each binding 
pose of free binding simulations at various ionic strengths. The binding energies decreased 
as the ionic strength increased indicating a stronger screening effect. But, the relative 
binding energies of three modes at different ionic strength are quite similar, supporting the 
use of MM-GBSA in ranking poses (ΔΔE=0.0, 4.6 and 6.5 kcal/mol for bottom, top and 
groove binding modes). Clearly, both MM-PBSA and MM-GBSA data indicates the most 




was observed to convert into the end binding mode. Thus, the groove binding is likely an 
intermediate state of end binding mode.   
3.5 Discussion 
G-quadruplex DNA has been gaining increasing attention as a promising target for 
cancer therapeutics(Biffi et al., 2014). The binding of BRACO19 to the G-quadruplex 
depends on its ability to π-π stack onto the G-quadruplex which is facilitated by its 
planarity. Molecular dynamics binding simulations and MM-PBSA binding energy 
calculations were utilized in this study, to analyze the binding pathway of BRACO19 to a 
telomeric DNA G-quadruplex. To tackle the fore-mentioned question, whether the latest 
AMBER DNA force field (OL15) is accurate enough to probe the binding pose of 
BRACO19 to G-quadruplex, the complex obtained from the simulation of the apo form 
and a free BRACO19 was compared to the simulated structure of the experimental X-ray 
crystal structure of the bound form (PDB ID: 3CE5). Comparing with an NMR solved 
structure would have been an ideal practice, but due to the unavailability of such NMR 
structure, X-ray solved crystal structure was used. Because of the crystal packing 
constraints, the potential AT-tetrad that could be formed by the bases T1, A2, T13 and A14 
was disrupted and instead the AT tetrad was formed by A2, T13, A14 and the T24 (Figure 
31) of different chains, thus disrupting the pairing of T24 with T12 of its respective chain. 
In the previous X-ray study,(Chung et al., 2013a) only two binding modes were observed, 
in which BRACO19 intercalates at the bottom of the G-tetrad and stack on the top of the 
ATAT-tetrad (Figure 30A). Stability simulations were conducted on these two crystal 
binding poses and illustrated the loss of planarity of BRACO19 in the bottom mode and 




bottom pose, which is consistent with the bottom binding trajectory of our free binding 
simulations. Clearly, the lack of the crystal packing constraints led to these changes. 
Therefore, the relaxation by MD simulations generated better solution reference structures 











Figure 44. H-bond network indicating maximum number of H-bonds possible in G-tetrad 




Our free binding simulations found that BRACO19 binds to the same telomeric 
DNA G-quadruplex structure in three different modes: Top stacking (11.9% total 
population), bottom intercalation (51.1% total population), and in the groove (9.6% total 
population). The bottom intercalation and top stacking mode resemble the BRACO19 
binding pose in the crystal structure. Our MM-PBSA/MM-GBSA and trajectory analysis 
show the bottom intercalation mode to be more stable than top stacking mode or groove 
binding mode. The apo form of the G-quadruplex in the crystal (Figure 30E &F) is known 
to have three G-tetrads whereas the top stacking and groove binding mode from the 




the ATAT-tetrad every adenine and thymine forms 6 H-bonds with adjacent thymine and 
adenine respectively (Figure 44) and in T-dyad, the thymine bases share 2 H-bonds with 
each other. The detailed analysis of number of H-bonds in each predefined layer is 
illustrated in Figure 71. Interestingly, the direct alignment type of an intra-quadruplex 
ATAT-tetrad observed in our simulation is different from the slipped alignment type of 
ATAT-tetrad identified by the previous NMR study of d(GAGCAGGT) sequence in 1M 
NaCl solution under which it forms a head-to-head dimeric quadruplex containing 
sequentially stacked GCGC, GGGG and slipped ATAT tetrads.(Zhang et al., 2001) This 
intra-quadruplex ATAT-tetrad is also different from the inter-quadruplex ATAT-tetrad that 
was observed in the crystal structure 3CE5 (Figure 31), although both share the similar 
geometry and H-bond pattern. Therefore, further experimental evidence is required to 
prove our prediction of the direct intra-quadruplex ATAT-tetrad. In the groove binding 
mode, T6 flipped out to facilitate BRACO19 insertion. A notable speculation in this study 
is that the groove binding mode is likely to be an intermediate stage in the process of 
achieving the final stable end stacking mode, which has been observed in our early study 
of binding of RHPS4 to human telomeric G-quadruplex(Kelly Mulholland et al., 2017) and 
in a study of binding of BRACO19 to a single stranded parallel telomeric G-quadruplex 
(to be published).  
The fore mentioned conformational differences between the apo and holo form of 
the G-quadruplex (i.e. the bottom intercalation mode) in the crystal structure were partially 
reproduced by the simulations. First, as to the flipping out of T6, T7 and A8 in the crystal 
complex structure (Figure 37C and 37E), the flipping out of the latter two was observed in 




and A14 in the crystal structure, this was observed in both bottom intercalation trajectories 
(Figure 38). In addition, further optimization of the bottom intercalation was observed in 
the simulation: while the T12 and T24 are not yet paired in the X-ray crystal structure 
(Figure 31), this T-dyad was formed in the simulation. As a result, BRACO19 is 
intercalated between the G-tetrad formed by residues 5, 11, 17 and 23 and the T-dyad by 
residues 12 and 24. The intercalation between G-tetrad and T-dyad increased the ligand 
binding energy to the G-quadruplex. 
The planarity of BRACO19 central rings permits the compound to stack on top and 
intercalate at the bottom of telomeric G-quadruplex. For this reason, planarity is a critical 
feature to be considered in developing G-quadruplex specific ligands. A planar scaffold 
not only increases the binding selectivity, but also boosts the intercalation thus increasing 
overall binding affinity. These findings may aid future attempts at creating a promising 
telomeric G-quadruplex stabilizer with large central rings. 
The dihedral angles of the 3 G-tetrads in both stability simulation and free binding 
simulations have low fluctuations and are consistent through the binding process. The 
dihedral angles of the terminal layers, ATAT-tetrad and T-dyad demonstrated more 
fluctuations. The torsion angle analysis indicated that the conformational changes are 
characterized mainly by α, γ, ε and ζ and in some cases, changes in χ dihedral angle. And 
the recent corrections (εζOL1, εζOL1and χOL4) in the AMBER OL15 DNA force field 
appears to provide a more balanced dihedral angle sampling which contributed to a good 





Computational methods are getting more and more significant in drug discovery as 
they provide detailed structural information. Molecular dynamics binding simulations, 
MM-PBSA and MM-GBSA binding energy calculations were utilized in this study, to 
characterize binding modes of BRACO19 to a telomeric DNA parallel G-quadruplex at 
physiological solution conditions and validate the utilization of latest AMBER DNA force 
field (OL15) with recent corrections βOL1, εζOL1 and χOL4 coupled with GAFF2 ligand 
force field in studying G-quadruplex in complex with a ligand. Three binding modes have 
been identified: top stacking, bottom intercalation and groove binding. Bottom 
intercalation and top stacking resembles very well the binding pose in the X-ray solved 
crystal structure of the same telomeric G-quadruplex with BRACO19. The groove binding 
mode is likely to be an intermediate state leading to the end binding mode. A flip-insertion 
mechanism was observed in the bottom intercalation mode, during which the flipping out 
of the bases make space for ligand insertion, followed by the flipping back of the bases to 
increase the stability of the complex. Formation of an intra-quadruplex ATAT-tetrad has 
been observed for the first time. Torsion angle analysis indicated good sampling of dihedral 




Chapter 4  
Binding of BRACO19 to a Telomeric G-Quadruplex DNA Probed by All-Atom 
Molecular Dynamics Simulations with Explicit Solvent 
4.1 Abstract 
High efficacy is displayed by the potently binding human telomeric DNA G-
quadruplex drug, BRACO19, in inhibition of tumor cell growth. Although, the 
improvement of its’ 62-fold preferential binding affinity towards DNA G-quadruplex over 
DNA duplex remains to be a challenge. The crystal structure of BRACO19 in complex 
with neither single-stranded telomeric DNA G-quadruplexes nor B-DNA duplex is 
available yet. Consequently, the characteristic binding nature of BRACO19 and these DNA 
forms remains elusive. In this study, the binding pathway of BRACO19 is characterized 
by simulating 200 ns MD binding simulations with a free ligand (BRACO19) to a DNA 
duplex and three different topological folds of the human telomeric DNA G-quadruplex 
(parallel, antiparallel and hybrid). Groove binding mode was found to be the most stable 
binding mode for the duplex and top stacking mode for parallel G-quadruplex, antiparallel 
and hybrid G-quadruplexes. The non-existential binding selectivity of BRACO19 can be 
accounted to the similar binding affinities of groove binding to both the duplex and the G-
quadruplex. For that reason, a modification should be induced such that this prospective 
ligand destabilizes binding to the duplex form but stabilizes the G-quadruplex binding. 
Such modification can improve this mere 62-fold binding selectivity toward the G-
quadruplex. Furthermore, the groove binding mode was found to be an intermediate stage 





The formation of the first therapeutically important G-quadruplex was observed in 
the single stranded overhang of human telomeric DNA.(J. Debray et al., 2009; Doluca, 
Withers, & Filichev, 2013a) The single stranded 3’ overhang (100-200 nucleotides) is the 
termini of the human telomeric DNA which contains numerous repeats of d(TTAGGG) 
sequences and is capped by Shelterin complexes.(Chung et al., 2013c; de Lange, 2005a; 
Moyzis et al., 1988a; Wright, Tesmer, Huffman, Levene, & Shay, 1997b) Shelterin 
complexes provides protection against nuclease attacks, chromosomal end-to-end fusion 
and gene erosion at cell divisions.(Palm & de Lange, 2008) After each cell replication, the 
telomere truncates by 50-200 base pairs and when the telomere is exhausted and Hayflick 
limit is reached, cell senescence and apoptosis are triggered.(Harley, Futcher, & Greider, 
1990a; Zakian, 1995a). 
In cancer cells, a reverse transcriptase called telomerase adds nucleotides to the 
telomere thus immortalizing the cells. (Greider & Blackburn, 1989b; Moorhouse et al., 
2006a) Telomerase is found to be overexpressed in 80-85% of tumor cells. It can be 
logically concluded that telomerase inhibition is a valid therapeutic approach in cancer 
treatment. But the challenges with this approach are (i) there is a time delay in which the 
telomere length needs to be established for the ultimate apoptosis trigger(Asai et al., 2003; 
Harley et al., 1990a; Shay & Wright, 2006) and (ii) studies suggest an alternate mechanism 
for telomerase maintenance might be activated upon telomerase inhibition.(Bechter, Zou, 
Walker, Wright, & Shay, 2004; Dunham, Neumann, Fasching, & Reddel, 2000; Hu et al., 
2012) It has been reported that the telomere cannot be hybridized by telomerase when the 




Prescott, 1991a) Consequently, stabilizing the telomeric G-quadruplex adopted by 
guanidine-rich single stranded 3’ overhang which will be perceived as DNA damage and 
stimulates cell apoptosis. (Denchi & de Lange, 2007a; Doluca et al., 2013a)  
G-quadruplexes can be formed from a single or double stranded DNA duplex. It 
has been experimentally established that the telomeric sequences can fold into four 
topologies in dilute solutions; hybrid [3+1] (PDB IDs: 2HY9 and 2JPZ), parallel (PDB ID: 
1KF1), one 2-tetrad antiparallel and one 3- tetrad antiparallel (PDB ID: 143D) folds. And 
this folding depend on sequence, ions and presence of small molecules.(Hänsel et al., 
2011a) Traditional studies suggest that the polymorphism is lost in 40% PEG or 50% 
ethanol solutions, in other words dehydrated solutions, parallel stranded conformation 
prevails. Concluding that parallel G-quadruplex is biologically relevant. Many studies were 
reported to develop lead compounds targeting them. Hansel et al suggested that parallel G-
quadruplex might not be the most prevalent form and other topologies need to be studied 
to understand and design lead compounds with better binding affinities and 
selectivity.(Hänsel et al., 2011a) 
BRACO19, tri-substituted acridine shown in figure 30, was logically designed with 
computer modelling by understanding the structural requirements of the parallel-stranded 
G-quadruplex binding site.(Yang & Okamoto, 2010a) BRACO19 has been reported to 
inhibit telomerase causing telomere shortening(Incles et al., 2004) and its experimental in-
vivo activity has been reported (Table 110). It was also reported that BRACO19 
demonstrated broad anti-viral activity by stabilizing the G-quadruplexes found in pro-viral 
DNA.(Perrone et al., 2014) Lack of selectivity towards G-quadruplex over duplex DNA is 




achieve higher selectivity (in the order of 10
5
), better understanding of characteristic 
binding of BRACO19 with DNA G-quadruplex and duplex DNA is required.  
The only available crystal structure with BRACO19 (PDB ID: 3CE5) is double 
stranded with a parallel G-quadruplex arrangement. The G-quadruplex asymmetrically 
interacts with the ligand via π–π interactions with the guanine bases, stacking the K+ in-
line. Computational studies reported that homologous variation of the side chains decreases 
the binding affinity (Campbell, Parkinson, Reszka, & Neidle, 2008) although these studies 
might be irrelevant as the telomeric overhang that folds into a G-quadruplex is single strand 
DNA. It is also to be noted that not many studies could be found on other scaffolds i.e., 
anti-parallel and hybrid.  
Debray et al synthesized and evaluated fused bis-pyrimidinoacridines, pentacyclic 
analogs of BRACO19 in order to understand the interactions of these analogs with the G-
quadruplex. The analogs were docked onto DNA G-quadruplex (PDB ID: 22AG), and 
DNA-duplex (PDB ID: DS17) and parallel G-quadruplex with BRACO19 (PDB ID: 3CE5) 
in the binding site.(Julien Debray et al., 2009) Xue et al synthesized and docked Neomycin-
Perylene conjugate onto the antiparallel G-quadruplex. Their docking data indicated that 
perylene moiety stacked onto the DNA bases and the two neomycin units occupied two G-
quadruplex grooves.(Xue, Ranjan, & Arya, 2011) Long et al introduced a peptidyl group 
on benzo-furo-quinoline derivatives; and their combined experimental and molecular 
docking data using parallel G-quadruplex suggest that the peptidyl group increased their 
selectivity significantly towards telomeric DNA quadruplex over duplex DNA.(Long et al., 
2012) Alcaro et al identified and characterized novel G-quadruplex binders by docking-




parallel and antiparallel folds.(Alcaro et al., 2013) Their docking data showed that most of 
the ligands stacked at the bottom of 1KF1 and 2HY9, but in the case of 143D and 2JPZ 
most of the ligands docked laterally. Multiple computational methods including 
pharmacophore modeling, shape-based modeling and docking were employed on DNA G-
quadruplexes (PDB IDs: 3SC8, 3UYH, 3CE5 and 3R6R) and lead candidates with 
promising potency were identified.(Kaserer et al., 2016) Nonetheless, it is well known that 
the docking with a rigid receptor might lead to incorrect binding modes and poor docking 
scores, therefore eliminating a prospective lead compound.(Mohan, Gibbs, Cummings, 
Jaeger, & DesJarlais, 2005) 
G-quadruplexes in complex with BRACO19 and various ligands have been widely 
studied using molecular dynamic (MD) simulations. Moore et al conducted MD 
simulations to investigate the structure-activity relationships of tri-substituted acridines 
analogs (BRACO19 analogs) and a modelled 22mer parallel G-quadruplex.(Moore et al., 
2006b) Hou et al revealed H-bonds to be the major contributors for stability of the G-
quadruplex and ligand-quadruplex complex by conducting stability simulations on G-
quadruplex-ligand complexes involving BRACO19 and 5 other ligands, known for affinity 
towards DNA G-quadruplex.(J. Q. Hou et al., 2010b) Dhamodharan et al advised end-
stacking to be the favored binding mode after docking bis-quinolinium and bis-pyridinium 
derivatives of 1,8-naphthyridine onto antiparallel G-quadruplex and consequently, 
conducting MD simulations. (Dhamodharan, Harikrishna, Jagadeeswaran, Halder, & 
Pradeepkumar, 2012a) However, Jain et al reported that both end-stacking and groove-
binding were favored after docking dimeric 1,3-phenylene-bis(piperazinyl 




Maji, Muniyappa, & Bhattacharya, 2012b) Ungvarsky et al characterized the binding poses 
of a novel set of BRACO19 derivatives to the human telomeric parallel G-quadruplex by 
successfully employing docking and MD simulations.(Ungvarsky et al., 2014b) Zhou et al 
attempted to understand the ligand unbinding from G-quadruplex using steered molecular 
dynamics and umbrella simulations.(J. K. Zhou, Yang, & Sheu, 2015b). Recently 
Diveshkumar et al conducted, by docking and MD simulation studies on various G-
quadruplexes (PDB IDs: 2L7V, 2O3M, 1KF1, 143D, and 2MB3) and identified indolyl, 
methylene-indanone scaffolds which demonstrate selectivity towards parallel promoter G-









Figure 45. Structure of human telomeric DNA duplex (A), human telomeric parallel DNA 
quadruplex (PDB ID: 1KF1) (B), human telomeric antiparallel DNA quadruplex (PDB ID: 
143D) (C), and human telomeric hybrid DNA quadruplex (PDB ID: 2HY9) (D). 5’ and 3’ 








In this study, the binding pathway of BRACO19 to parallel, anti-parallel, hybrid 
DNA G-quadruplex and duplex DNA is characterized by conducting molecular dynamics 
binding simulations. In this study, the binding pathway of BRACO19 to parallel, anti-
parallel, hybrid DNA G-quadruplex and duplex DNA is characterized by conducting 
molecular dynamics binding simulations. MD free ligand binding simulations in which no 
constraints are placed on the relative position of the ligand were utilized to probe the 
binding pathway and mechanism of BRACO19 to the human telomeric parallel G-
quadruplex DNA. Major binding poses, (top binding, end stacking, bottom binding and 
groove binding) were identified and detailed binding pathways were characterized. The 
dynamic and energetic properties of the three major binding modes were thoroughly 
studied, providing vivid examples of induced-fit binding mechanism. The similar binding 
energy of the groove binding pose to the duplex and the G-quadruplexes may be 
responsible for the low selectivity of BRACO19. The binding pathway of BRACO19 to 
various G-quadruplexes is characterized using torsion angle parameters. This analysis 
indicated good sampling of dihedral angles and a good agreement with the experimental 










DNA Duplex + Unbound BRACO19 Parallel DNA G-Quadruplex + Unbound 
BRACO19 
  
Anti-parallel DNA Quadruplex + 
Unbound BRACO19 
Hybrid DNA Quadruplex + Unbound 
BRACO19 
  
Figure 46. Initial configuration of the simulation systems. 5’ and 3’ of the telomeric DNA 




A total of 4 DNA-ligand systems were constructed: B-DNA duplex structure of 
d([GC]10)2, X-ray crystal structure of the parallel telomeric DNA G-quadruplex, NMR 
solved anti-parallel telomeric DNA G-quadruplex and NMR-solved (3+1) hybrid telomeric 
DNA G-quadruplex (figure 46). One B-DNA duplex structure of d([GC]10)2, built using 
Maestro program, one X-ray solved human telomeric parallel G-quadruplex and two NMR 
solved human telomeric G-quadruplex structure were each used to construct four unbound 
DNA-ligand systems with a BRACO19 molecule that was 10 Å away from the DNA 




solvate the unbound system. And it was neutralized by K+. The DNA structures were 
represented by a refined version of the AMBER DNA OL15 (i.e. parm99bsc0(Pérez et al., 
2007) +χOL4 (Krepl et al., 2012b)+ ε/ζOL1(Zgarbova et al., 2013)+ βOL1(Zgarbova et al., 
2015) updates), water was represented by TIP3P model(Jorgensen, Chandrasekhar, 
Madura, Impey, & Klein, 1983c) and the K+ ions were represented by the K+ model 
developed by Cheatham group.(Joung & Cheatham, 2008b) The standard AMBER 
protocol was used to obtain the force field for the BRACO19 molecule: after the geometry 
optimization of the BRACO19 at the HF/6-31G* level, the molecular electrostatic potential 
(MEP) of the BRACO19 molecule was calculated at the same theory level; then the partial 
charges of BRACO19 atoms was determined by MEP using Restrained Electrostatic 
Potential/RESP method with two stage fitting;(Bayly, Cieplak, Cornell, & Kollman, 
1993a) and the AMBER GAFF2(Case et al., 2016) force field provided the rest of the force 
field parameters. The nucleic acid simulations have been widely practiced in AMBER 
DNA force fields.(Cosconati et al., 2010; Fadrna et al., 2009; Lavery et al., 2010; A. 
Mukherjee, Lavery, Bagchi, & Hynes, 2008) In our studies, the binding pathway of 
doxorubicin(Lei, Wang, & Wu, 2012b) and telomestatin(K. Mulholland & Wu, 2016), anti-
cancer drugs, to the B-DNA fragment(Lei et al., 2012b) and to the human telomeric hybrid 
G-quadruplex(K. Mulholland & Wu, 2016), respectively have been simulated. 
4.3.2 Simulation protocols. The ten production runs for all systems were 
conducted using the AMBER 16 simulation package.(Case et al., 2016) The detailed 
protocol followed our previous studies.(Lei et al., 2012b; K. Mulholland & Wu, 2016) 
After minimizing the energy, the Maxwell-Boltzmann distribution was followed in using 




Better sampling of binding poses and pathway was enabled by multiple independent 
simulations. To equilibrate the system density, a 1.0 µs production run at 300 K which 
included a short 1.0 ns MD simulation in the NPT ensemble mode (constant pressure and 
temperature), where the DNA and ligand were subjected to Cartesian restraints (1.0 
kcal/mol/Å), and 200.0 ns (500 ns for one trajectory of parallel G-quadruplex) MD 
simulation in the NVT ensemble mode (constant volume and temperature). All bonds 
connecting hydrogen atoms were constrained by SHAKE(Ryckaert, Ciccotti, & Berendsen, 
1977b) which enabled a 2.0 fs time step in the simulations. Long-range electrostatic 
interactions under periodic boundary conditions were treated using the particle-mesh 
Ewald method(Essmann et al., 1995b) (the fourth order of the B-spline charge 
interpolation, charge grid spacing of ~1.0 Å; and direct sum tolerance of 10–5). The cutoff 
distance for short-range non-bonded interactions was 10 Å, with the long-range van der 
Waals interactions based on a uniform density approximation. To reduce the computation 
cost, a two-stage RESPA approach(Procacci & Berne, 1994b) was used to calculate non-
bonded forces where the short range forces were updated every step and the long range 
forces were updated every two steps. The Langevin thermostat with a coupling constant of 
2.0 ps was used to control the temperature. The trajectories were saved at 50.0 ps intervals 
for analysis. 
4.3.3 Convergence of simulations. The initial structure was used as a reference to 
calculate the root mean square deviation (RMSD) of DNA backbone. The stability of the 
DNA structures was indicated by the flat and small RMSDs (Figure 62, 64, 66 and 68). An 
atom-to-atom distance cutoff of 3.0 Å was used to calculate atom contacts between the 




the simulation systems (Figure 63, 65, 67 and 69). A complex with the number of atom 
contacts greater than 10 was defined as a stable complex. 
4.3.4 Binding mode identification. Accounting to the stability of the DNA 
backbone in the binding process, the DNA backbone of the stable complexes was aligned 
by a least square fitting. Daura algorithm (Daura et al., 1999b) was used to cluster the 
aligned complexes into different structural families based on the 2 Å pair-wise RMSD 
cutoff of the BRACO19 only without ligand fit. The centroid structure was defined as a 
structure with the largest number of neighbors in the structural family. And this structural 
family was represented by this centroid structure. Based on visual inspection, super-
families corresponding to major binding modes were formed by merging the centroid 
structures. 
4.3.5 Order parameters. The DNA-drug binding process was characterized by 
using five order parameters: hydrogen bond analysis, drug-base dihedral angle, ligand 
RMSD, center-to-center and K+-K+ distance (R) and MM-GBSA binding energy (ΔE). A 
hydrogen bond was defined by 3.5Å distance cutoff between H-bond donor and H-bond 
acceptor and 120° donor-H-acceptor angle cutoff. The hydrogen bonds were calculated for 
the top/first, middle/second and bottom/third base layers. For the duplex, the three base 
layers were defined based on the drug insertion position. For the three G-quadruplexes, the 
three G-tetrads were defined so that 5’ is close to the first G-tetrad. The dihedral angle 
between the plane of the stable G-tetrad layer of the DNA that is close to drug binding site 
and the BRACO19’s ring plane was defined as the dihedral angle. After aligning the DNA, 
the ligand RMSD was calculated with reference to the first frame of the trajectory. The 




distance (R). The distance between the K+ ions present in the DNA G-quadruplex was 
defined as K+-K+ distance. The energetics of the bound complexes were analyzed using 
MM-GBSA(P. A. Kollman et al., 2000) (Molecular Mechanics Generalized Born-Surface 
Area) module in the AMBER package (GB1 model with salt concentration of 0.2 M, 
mBondi radii set, and surface tension of 0.0072 kcal/Å2) to avoid the large energy 
fluctuation of the explicit solvent.  
It was reported that even when considering the relative solvation free energy, good 
predictions can be made for charged molecules by the GB models on the hydration free 
energy.(Kongsted, Soderhjelm, & Ryde, 2009a) Under this assumption, in this study, ions 
were removed from charged DNA systems. This was already validated in our previous 
study, in which this MMGBSA protocol successfully assessed the binding energy of 
doxorubicin, an anti-cancer drug, to a B-DNA fragment (d(CGATCG)2).(Lei, Wang, & 
Wu, 2012c) Under comparable entropic terms, the relative binding free energy estimated 
by the MMGBSA binding energies can be used to rank drugs or their binding poses if a 
single molecule is considered.(Kongsted, Soderhjelm, & Ryde, 2009b) It has been 
established by systematic benchmarking studies up to 1864 crystal complexes that ranking 
of the ligand binding affinity can be achieved by relative MM-GBSA binding energy 
calculations.(Hou, Wang, Li, & Wang, 2010, 2011; P. Kollman et al., 2000; Sun, Li, Tian, 
Xub, & Hou, 2014; Xu, Sun, Li, Wang, & Hou, 2013) The standard backbone dihedral 
angles (α, β, γ, δ, ε and ζ) around the covalent bonds of the deoxyribose and χ about the 















































































Figure 47. Simulated structures of human telomeric DNA duplex (A), human telomeric 
parallel DNA quadruplex (PDB ID: 1KF1) (B), human telomeric antiparallel DNA 
quadruplex (PDB ID: 143D) (C), and human telomeric hybrid DNA quadruplex (PDB ID: 
2HY9) (D) in complex with BRACO19. A-D: Top pose (left), Bottom (middle) and groove 
(right) 5’ and 3’ of the telomeric DNA are indicated by a red and blue ball, respectively 




4.4.1 Multiple drug binding modes were observed in binding simulations. 
Starting from an unbound state, ten production runs for all four systems were simulated. 
The convergence of the binding simulations was confirmed (see the method section). The 
last snapshots of all the simulated trajectories of duplex are listed in figure 48 and they 
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Run 04 (Bottom) Run 09 (Groove) 
 
   
Run 05 (Groove) Run 10 (Groove) 
    
Figure 48. Last snapshots of 10 DNA duplex and BRACO19 simulations. 5’ and 3’ of the 




And the last snapshots of all the simulated trajectories of G-quadruplexes are listed 
in figure 49, 50 and 51. They indicate the stability of the structures; the G-tetrads were 
maintained and the K+ ions retained their position in almost all the trajectories. It is to be 
noted that in figure 49, run 07 and 09 the K+ ion moved out of the quadruplex and this 
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Figure 49. Last snapshots of 10 parallel telomeric DNA G-quadruplex and BRACO19 
simulations. 5’ and 3’ of the telomeric DNA G-quadruplex are indicated by a red and blue 
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Figure 50. Last snapshots of 10 anti-parallel telomeric DNA G-quadruplex and BRACO19 
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Figure 51. Last snapshots of 10 hybrid telomeric DNA G-quadruplex and BRACO19 
simulations. 5’ and 3’ of the telomeric DNA G-quadruplex are indicated by a red and blue 
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Multiple binding sites were observed in the ten duplex DNA-BRACO19 
trajectories. The clustering analysis described in the methods section was employed to 
categorize the stable complexes, extracted from these trajectories, into structural families. 
By setting a threshold of 1% population, 14 structural families of complexes were 
identified. These 8 structural families were further merged into three binding modes: 
groove binding, top stacking and bottom stacking. Binding to the groove of the duplex 
accounted for 81% of the total population. Additionally, end stacking to the top of the 
duplex accounted for 4% and end stacking to the bottom of the duplex made up 2% of the 




BRACO19 trajectories. The same clustering analysis was employed to categorize the stable 
complexes, extracted from these trajectories, into 10 structural families. Two binding 
modes were observed: top stacking and groove binding. Top stacking to the parallel G-
quadruplex DNA accounted for 56% and groove binding for 41% of the total population. 
Multiple binding sites were observed in the ten antiparallel G-quadruplex DNA-BRACO19 
trajectories. The same clustering analysis was employed to categorize the stable complexes, 
extracted from these trajectories, into 9 structural families. Three binding modes were 
observed: top, bottom and groove binding. Bottom binding to the antiparallel G-quadruplex 
DNA accounted for 47%, top binding for 33% and groove binding for 21% of the total 
population. Multiple binding sites were observed in the ten hybrid G-quadruplex DNA-
BRACO19 trajectories. The same clustering analysis was employed to categorize the stable 
complexes, extracted from these trajectories, into 12 structural families. Three binding 
modes were observed: top, groove and bottom binding. Groove binding to the hybrid G-
quadruplex DNA accounted for 74%, Top binding for 19%, and bottom binding for 9% of 





4.4.2 VDW interaction contributes most to the total binding energy, ranking 




Table 114  
MM-GBSA binding energy (kcal/mol) of BRACO19 to human telomeric DNA duplex and 
Quadruplexes. 













15TS -28.9±4.0 -2.3±0.5 -5.2±3.1 2.7±1.2 -33.7±5.3 28.6 
16BB -28.4±4.1 -2.2±0.5 -4.8±3.2 0.8±3.8 -34.6±5.7 27.7 
17GB -57.9±9.5 -5.2±0.7 -3.9±4.5 5.2±2.8 -61.7±8.0 0.6 
Parallel 
Quad 
TS -63.1±5.7 -5.2±0.6 -1.9±4.4 7.9±5.2 -62.3±4.5 0 




TS -41.5±11.4 -4.0±1.1 -8.5±4.3 0.1±4.6 -53.9±5.8 8.4 
BB -29.1±9.0 -2.5±0.8 -9.2±3.0 -2.1±4.4 -42.8±4.1 19.5 
GB -43.0±6.0 -3.4±0.5 -7.5±2.6 10.9±2.3 -43.1±7.2 19.2 
Hybrid 
Quad 
TS -44.2±11.4 -4.3±1.0 -12.1±5.0 20.0±9.2 -40.5±5.4 21.8 
BB -25.7±5.8 -2.8±0.7 -16.3±6.0 15.8±8.5 -29±12.9 33.3 




MM-GBSA binding energy calculations were carried out as depicted in methods 
section to examine the relative binding affinities major binding modes of BRACO19 with 
respect to DNA and summarized in Table 114. Of the three binding modes of BRACO19 
to the DNA duplex, the best binding energy was in the groove binding mode (-69.5±8.0 
kcal/mol), followed by the top stacking mode (-34.8±5.3 kcal/mol).  
                                                             
9 Change of van der Waals energy in gas phase upon complex formation 
10 Change of surface area term change upon complex formation 
11 Change of GBELE generalized Born term + gas phase electrostatic energy upon complex formation 
12 Change of conformational energy upon complex formation 
13 Change of total potential energy in water upon complex formation (VDW+SUR+GBELE+CONF) 
14 Change in binding energy with a reference to top stacking parallel G-quadruplex 
15 Top Stacking 
16 Bottom Binding 




VDW packing responsible for the VDW energy contribution governed the binding 
energy order of the three modes. The VDW contribution in the groove mode (-59.8±5.5 
kcal/mol) points out that in the groove binding mode, one side of BRACO19 was still 
exposed to solvent. BRACO19 bound to parallel G-quadruplex DNA in two binding poses. 
Top stacking (-72.1±4.5kcal/mol) was the most, making the groove binding (-40.3±7.2 
kcal/mol) being the least stable of the two. BRACO19 bound to antiparallel G-quadruplex 
DNA in three binding poses. Top binding (-60.9±5.8 kcal/mol) was the most stable of the 
three with groove binding exhibiting a binding energy of only -57.2±7.2kcal/mol. Bottom 
binding was the lowest with a binding energy of -45.2±4.1kcal/mol. BRACO19 bound to 
hybrid G-quadruplex DNA in three binding poses as well. Top binding (-63.4±5.4 
kcal/mol) was the most stable of the three, followed by groove binding (-56.8±5.1 











Figure 52. A representative groove binding trajectory of the DNA duplex. Top: 
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue 
ball, respectively. Bottom: An order parameter plot depicting number of hydrogen bonds 
present in first base pair (green), second base pair (red) and third base pair (blue) layers of 
the DNA structure (figure 45), the drug-base dihedral angle, receptor (red) and ligand 
(black) RMSD relative to the original crystal pose, center-to-center distance and MM-
GBSA binding energy (ΔE) (cf. methods section for definition).  
    
0 ns 3 ns 4 ns 5 ns 
    




The representative trajectory for the groove binding of BRACO19 to the duplex 
DNA are characterized in Figure 52. In all ten binding trajectories, the DNA showed low 
structural fluctuation with RMSD of 2.4 Å (Figure 62) and the hydrogen bonds between 
the base pairs were maintained. In the representative trajectory of BRACO19 binding to 
the groove of the human telomeric duplex DNA in figure 52, an initial interaction was 
observed as early as 3 ns and the final binding pose was achieved at an astounding 14 ns 
and was maintained throughout the remainder of the trajectory. The limited fluctuation in 
the five order parameters explains the limited structural dynamics. The other representative 
trajectories of BRACO19 top stacking, groove binding, bottom stacking also exhibited 










Figure 53. A representative top stacking trajectory of the parallel G-quadruplex. Top: 
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue 
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are 
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter 
plot depicting number of hydrogen bonds present in first G4 (green), second G4 (red) and 
third G4 (blue) layers of the DNA structure (Figure 45), the drug-base dihedral angle, 
receptor (red) and ligand (black) RMSD relative to the original crystal pose, center-to-
center distance (R/black) and K+-K+ distance (R/red) and MM-GBSA binding energy (ΔE) 
(cf. methods section for definition).  
    








The representative trajectory for the top stacking mode of BRACO19 to the parallel 
human telomeric G-quadruplex DNA are characterized in figure 53. In all ten binding 
trajectories, the DNA showed low structural fluctuation with RMSD of 2.4 Å (Figure 64) 
and the hydrogen bonds in the three G-tetrads were maintained. In the representative 
trajectory of BRACO19 binding to the top of the human telomeric parallel G-quadruplex 
DNA in figure 53, an initial interaction to the complex at 8 ns and attaining the stable 
groove binding pose at 19 ns. However, on further simulation to 500 ns, at exactly 463 ns 
BRACO19 was stacked on top of the parallel G-quadruplex. It can be inferred that groove 
binding is an intermediate state for top stacking mode. This further simulation also showed 
that the potassium ion from the G-quadruplex moved out followed by the disruption of the 
third G-tetrad layer of the G- quadruplex inferring that the K+ ions are essential for the 
stability of the G-quadruplex. The binding energy for top stacking fluctuated between -60 
and -75 kcal/mol while bottom stacking varied between -35 and -45 kcal/mol after attaining 






Figure 54. Comparison for the backbone torsion angles of residue T6 between the free 
ligand binding simulation (red) of the top stacking mode of the parallel G-quadruplex and 
the stability simulation of the crystal structure (black) of the parallel G-quadruplex. Top: 




Dihedral angles of all DNA bases in the simulated parallel G-quadruplex were 
analyzed. The dihedral angles of the G-tetrads in free ligand binding simulations indicate 
low fluctuations and are consistent through the binding process. Major fluctuations were 
observed in the terminal residues, T6 in particular is discussed here as it demonstrates 
highest fluctuation. T6 flipped out at 15 ns and flipped back at 45 ns, flipped out at 69 ns 
and flipped in at 100 ns and it finally flipped out at 114 ns and remained same throughout 
the rest of the trajectory. This flipping out of the base is mainly characterized by α, β, γ and 











Figure 55. A representative top stacking trajectory of the anti-parallel G-quadruplex. Top: 
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue 
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are 
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter 
plot depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4 
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure (Figure 45), the 
drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative to the original 
crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and MM-
GBSA binding energy (ΔE) (cf. methods section for definition). 
    
0 ns 5 ns 8 ns 13 ns 
    






Figure 56. Comparison for the backbone torsion angles of residue T05 between the free 
ligand binding simulation (red) of the top stacking trajectory of the anti-parallel G-
quadruplex and the stability simulation of the crystal structure (black) of the anti-parallel 




The representative trajectory for the top stacking mode of BRACO19 to the 
antiparallel human telomeric G-quadruplex DNA are characterized in figure 55. In all ten 
binding trajectories, the DNA showed high structural fluctuation in four trajectories with 
RMSD of 3.2 Å (Figure 66), the hydrogen bonds in the three G-tetrads were maintained 
and the distance between K+ ions remained stable in all trajectories. The representative 
trajectories of top stacking of BRACO19 with the human telomeric antiparallel G-
quadruplex DNA, showed an initial interaction at an early 5 ns and the final binding pose 
was achieved at an astonishing 42 ns and was maintained throughout the rest of the 
trajectory. The limited structural dynamics was explained by the limited fluctuation in the 
five order parameters.  The representative trajectories of the groove binding and bottom 
binding are similar to the top binding trajectory with a rapid binding and limited fluctuation 
of order parameters. Early interaction at 1 and 5 ns respectively and attainment of final 
binding pose by 16 and 55 ns respectively. The other representative trajectories of 
BRACO19 top stacking, groove binding and bottom stacking also exhibited rapid binding 
and limited dynamics, binding to the complex at 19, 5 and 2 ns respectively and attaining 
the final binding pose at 117, 143 and 107 ns respectively and maintained it throughout the 
rest of the trajectories. The binding energy for top stacking and groove binding fluctuated 
between -55 and -65 kcal/mol while bottom stacking varied between -40 and -50 kcal/mol 
after attaining the steady binding pose. 
Dihedral angles of all DNA bases in the simulated anti-parallel G-quadruplex were 
analyzed. The dihedral angles of the G-tetrads in free ligand binding simulations indicate 
low fluctuations and are consistent through the binding process. Major fluctuations were 




highest fluctuation. Through the binding process BRACO19 majorly interacted with T5, it 
opened up as BRACO19 approached and at 29 ns, flipped out to let BRACO19 in, flipped 
back at 40 ns and it stayed open afterward while interacting with BRACO19. This flipping 
out of the base is mainly characterized by ε and ζ (figure 56). 
4.4.6 BRACO19 binds to the hybrid telomeric G-Quadruplex DNA, without 
inducing structural fluctuation. The representative trajectory for the top stacking of 
BRACO19 with respect to the hybrid human telomeric G-quadruplex DNA are 
characterized in figure 57. In all ten binding trajectories, the DNA showed high structural 
fluctuation in five trajectories with RMSD of 2.9 Å (Figure 68), the hydrogen bonds in the 
three G-tetrads were maintained and the distance between K+ ions remained stable in all 
trajectories. The representative trajectory of BRACO19 top stacking onto the hybrid G-
quadruplex DNA showed an initial interaction at 3 ns and the final binding pose was 
attained as early as 30 ns and was maintained throughout the rest of the trajectory. The 
limited structural dynamics was explained by the limited fluctuation in the five order 
parameters.  The representative trajectories of the groove binding and bottom binding are 
similar to the top binding trajectory with a rapid binding and limited fluctuation of order 
parameters. Early interaction at 2 and 9 ns respectively and final binding pose was attained 
by 13 and 51 ns respectively. The other representative trajectories of BRACO19 top 
stacking, groove binding and bottom stacking also exhibited rapid binding and limited 
dynamics. The binding energy for all binding modes varied between -55 and -65 kcal/mol 





Figure 57. A representative top binding trajectory of the hybrid G-quadruplex. Top: 
Representative structures with time annotation. 5’ and 3’ are indicated by a red and blue 
ball, respectively. Residues 1, 2, 13, 14 are indicated in purple and residues 12, 24 are 
indicated in red and the K+ ions are represented in yellow. Bottom: An order parameter 
plot depicting number of hydrogen bonds present in first (red), second G4 (cyan), third G4 
(blue), fourth G4 (black) and fifth (green) layers of the DNA structure (Figure 45), the 
drug-base dihedral angle, receptor (red) and ligand (black) RMSD relative to the original 
crystal pose, center-to-center distance (R/black) and K+-K+ distance (R/red) and MM-
GBSA binding energy (ΔE) (cf. methods section for definition).
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Figure 58. Comparison for the backbone torsion angles of residue T8 between the free 
ligand binding simulation (red) of the top binding trajectory of the hybrid G-quadruplex 
and the stability simulation of the crystal structure (black) of the hybrid G-quadruplex. 




Dihedral angles of all DNA bases in the simulated hybrid G-quadruplex were 
analyzed. The dihedral angles of the G-tetrads in free ligand binding simulations indicate 
low fluctuations and are consistent through the binding process. Major fluctuations were 
observed in the terminal residues, T8 in particular is discussed here as it demonstrates 
highest fluctuation. T8 flipped out upon simulation and remained flipped through the rest 
of the simulation except for a few ns after 38 ns and 143 ns. This flipping out of the base 
is mainly characterized by α, δ, ε and ζ (figure 58). 
4.5 Discussion 
After the recent discovery of the greater existence of G-quadruplex in malignant 
tumors than in normal tissues interest in G-quadruplex DNA as a promising target for 
cancer therapeutics has increased. BRACO19, one of the most effective G-quadruplex 
binding ligands, is a promising anticancer drug candidate, yet its low preferential binding 
affinity (about ~62-fold) to the telomeric single-stranded G-quadruplex DNA over duplex 
DNA remains to be enhanced. For better molecular insights, the binding of BRACO19 to 
a duplex 20mer DNA (d([GC]10)2) and to the parallel, antiparallel and hybrid telomeric G-
quadruplexes was investigated in this study using binding molecular dynamics simulations 
with a free ligand.  
Out of various binding modes for each system, the MM-GBSA binding energy 
calculations showed that the most stable binding pose was the groove binding mode for the 
duplex and the top stacking mode for the parallel G-quadruplex, the antiparallel G-
quadruplex and the hybrid G-quadruplex (figure 45).   The order of the relative binding 
energy of BRACO19 in these most stable poses are as follows: -72.1±4.5 kcal/mol; the top 




binding to the duplex DNA (2.6 kcal/mol) > -63.4±5.4 kcal/mol; the top stacking to the 
hybrid G-quadruplex (8.7 kcal/mol) > -60.9±5.8 kcal/mol; the top stacking to antiparallel 










Figure 59. (A) The experimental binding mode (PDB ID: 3CE5) of double stranded 
parallel telomeric DNA G-quadruplex (B) Major binding pose of simulated single stranded 




The combination of the long time (1 μs) stability and the large magnitude of these 
binding energies suggests an enthalpy driven binding is likely and the contribution of 
entropy to the binding free energy to be of minor importance. Analysis by breaking down 
the binding energy indicated that the VDW term makes the biggest contribution to the total 
binding energy (Table 114). This indication suggests introducing target or drug specific 
packing optimization as a prospect for further stabilization of the G-quadruplex. If these 
binding modes have comparable entropic energies and the parallel G-quadruplex is the 




BRACO19 binds preferentially to the telomeric G-quadruplexes than to the DNA duplex. 
This qualitatively explains the experimental observation of preferential binding affinity 
difference of BRACO19 on the two DNA forms. The emphasis is being directed to the fact 
that the binding energies of the groove binding mode of the duplex and top stacking mode 
of the G-quadruplex are comparable. This rationalizes the lack of binding selectivity of 
BRACO19 to the two DNA forms. For that reason, it can be suggested that a ligand 
modification that destabilizes the duplex groove binding mode but stabilizes the G-
quadruplex top stacking mode will enhances the binding selectivity of the ligand. For 
example, adding a planar ring fragment to the acridine would facilitate the top stacking 
rather than groove binding and increase the van deer Waals interactions there for increasing 
selectivity and binding affinity of the prospective drug towards the G-quadruplex. This 
suggestion is consistent with the original SAR data in the development of BRACO19 from 
prototype BSU6048 in which the addition of the ring at position 9 (makings of BRACO19) 
increased the drug selectivity from 10-fold to 62 fold   towards human telomeric G-
quadruplexes over duplex DNA. (Harrison, Gowan, Kelland, & Neidle, 1999; White et al., 
2007; Yang & Okamoto, 2010a)  And it is also to be noted that the sidechains on 3 and 6 
contribute to the groove binding of both DNA duplex and G-quadruplex which could be 
the reason behind low selectivity. So, suggestions can be made to reduce the length of these 
side chains. These side chains exist in protonated form at physiological pH however, Table 
114 indicates that the contribution of electrostatic interactions to the binding affinity is very 
low and therefore modifications can be suggested to the substituents at 3rd and 6th position 




hydrophobicity which could in fact increase the van der Waals interactions and reduction 
of the length of the side chains. 
The most stable binding mode of BRACO19 to the DNA duplex is the groove 
binding and the single stranded G-quadruplexes  is top stacking mode, which is evidently 
similar to the binding pose in the only X-ray solved crystal structure of a double stranded 
G-quadruplex in complex of BRACO19  (Figure 70). The plane of BRACO19 is parallel 
to the plane of G-tetrads. However, molecular details are different. In the groove binding 
mode of duplex and the top stacking mode of parallel G-quadruplex, antiparallel and hybrid 
G-quadruplex only one side of BRACO19 molecule interacted with the DNA. Lastly, the 
groove binding mode was observed to be an intermediate stage of top stacking mode. The 
dihedral angles of the 3 G-tetrads in free ligand binding simulations indicate low 
fluctuations and are consistent through the binding process. The torsion angle analysis 
indicated that the conformational changes are characterized mainly by α, β, γ, ε, and ζ and 
in some cases changes in χ dihedral angle. Significant overlap between in the histogram of 
free ligand binding simulation and crystal pose simulation indicate good prediction of the 






The detailed structural knowledge of the intramolecular human telomeric G-quadruplexes 
in complex with a ligand is required for the rational design of human telomeric G-
quadruplex binding drugs. In this study, molecular dynamics binding simulations were 
used to probe and understand the binding nature of BRACO19, a potent human telomeric 
G-quadruplex drug, to a B-DNA duplex and the three scaffolds of a single stranded human 
telomeric G-quadruplex. The most stable binding mode indicated by the MM-GBSA 
binding energy analysis for the duplex DNA is the groove binding mode and top stacking 
for parallel G-quadruplex, antiparallel and hybrid G-quadruplexes. The similar binding 
affinity of BRACO19’s groove binding mode with respect to both the duplex and the G-
quadruplexes explains its lack of preferential binding selectivity. Therefore, a ligand 
modification that destabilizes the duplex groove binding mode but stabilizes the G-
quadruplex top stacking mode will improve the binding selectivity of the ligand. Our study 
presents a successful example of the ability of molecular dynamic simulations with the 
latest AMBER force field to facilitate detailed structural and dynamic information which 





The study illustrated in Chapter 2, CADD in Boron therapeutics is under 
preparation for publication 
The study illustrated in Chapter 3, probing the binding mechanism of BRACO19 
and human telomeric DNA G-quadruplex is accepted for publication by Journal of 
Chemical Information and Modelling 
The study illustrated in Chapter 4, Binding of BRACO19 to a Telomeric G-
Quadruplex DNA Probed by All-Atom Molecular Dynamics Simulations with Explicit 
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Appendix A  





Figure 60. RMSD plot for each trajectory of parallel DNA G-quadruplex and BRACO19 





Figure 61. The contact number between parallel DNA G-quadruplex and BRACO19 for 




Appendix B  











Figure 63. The contact number between DNA duplex and BRACO19 for each trajectory 





Figure 64. RMSD plot for each trajectory of parallel DNA G-quadruplex and BRACO19 





Figure 65. The contact number between parallel DNA G-quadruplex and BRACO19 for 





Figure 66. RMSD plot for each trajectory of anti-parallel DNA G-quadruplex and 





Figure 67. The contact number between anti-parallel DNA G-quadruplex and BRACO19 





Figure 68. RMSD plot for each trajectory of hybrid DNA G-quadruplex and BRACO19 





Figure 69. The contact number between hybrid DNA G-quadruplex and BRACO19 for 




Appendix C  




Figure 70. 2D ligand-DNA interactions of BRACO19 in complex structures of (A) crystal 
bottom pose, (B) MD relaxed crystal bottom pose, (C) bottom binding pose from free 
binding simulations, (D) crystal top binding pose, (E) MD relaxed crystal top pose (F) top 
binding pose from free binding simulations and (G) groove binding pose from free binding 
simulations.  
 2D interactions 











































Figure 70 (continued)  
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Figure 70 (continued) 
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Figure 70 (continued)    
 2D interactions 





H-bonds AT-tetrad G-tetrad (1) T-dyad 
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Figure 71. H-bond network in the layers formed by DNA residues in the representative 
structure of (A) Crystal Bottom Pose, (B) MD Simulated Crystal Bottom Pose, (C) Bottom 
Binding Pose from Free MD Binding Simulations, (D) Crystal top binding Pose, (E) MD 
Simulated Crystal top Pose (F) top Binding Pose from Free MD Binding Simulations and 
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Figure 71 (continued) 
 
